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Background: Thyroid nodules are a common clinical problem, and differentiated thyroid cancer is becoming
increasingly prevalent. Since the publication of the American Thyroid Association’s guidelines for the man-
agement of these disorders was published in 2006, a large amount of new information has become available,
prompting a revision of the guidelines.
Methods: Relevant articles through December 2008 were reviewed by the task force and categorized by topic and
level of evidence according to a modified schema used by the United States Preventative Services Task Force.
Results: The revised guidelines for the management of thyroid nodules include recommendations regarding
initial evaluation, clinical and ultrasound criteria for fine-needle aspiration biopsy, interpretation of fine-needle
aspiration biopsy results, and management of benign thyroid nodules. Recommendations regarding the initial
management of thyroid cancer include those relating to optimal surgical management, radioiodine remnant
ablation, and suppression therapy using levothyroxine. Recommendations related to long-term management of
differentiated thyroid cancer include those related to surveillance for recurrent disease using ultrasound and
serum thyroglobulin as well as those related to management of recurrent and metastatic disease.
Conclusions: We created evidence-based recommendations in response to our appointment as an independent
task force by the American Thyroid Association to assist in the clinical management of patients with thyroid
nodules and differentiated thyroid cancer. They represent, in our opinion, contemporary optimal care for pa-
tients with these disorders.
Thyroid nodules are a common clinical problem. Epi-demiologic studies have shown the prevalence of palpa-
ble thyroid nodules to be approximately 5% in women and 1%
in men living in iodine-sufficient parts of the world (1,2). In
contrast, high-resolution ultrasound (US) can detect thyroid
nodules in 19–67% of randomly selected individuals with
higher frequencies in women and the elderly (3). The clinical
importance of thyroid nodules rests with the need to exclude
thyroid cancer which occurs in 5–15% depending on age, sex,
radiation exposure history, family history, and other factors
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(4,5). Differentiated thyroid cancer (DTC), which includes
papillary and follicular cancer, comprises the vast majority
(90%) of all thyroid cancers (6). In the United States, approx-
imately 37,200 new cases of thyroid cancer will be diagnosed
in 2009 (7). The yearly incidence has increased from 3.6 per
100,000 in 1973 to 8.7 per 100,000 in 2002, a 2.4-fold increase
( p< 0.001 for trend) and this trend appears to be continuing
(8). Almost the entire change has been attributed to an in-
crease in the incidence of papillary thyroid cancer (PTC),
which increased 2.9-fold between 1988 and 2002. Moreover,
49% of the rising incidence consisted of cancers measuring
1 cm or smaller and 87% consisted of cancers measuring 2 cm
or smaller (8). This tumor shift may be due to the increasing
use of neck ultrasonography and early diagnosis and treat-
ment (9), trends that are changing the initial treatment and
follow-up for many patients with thyroid cancer.
In 1996, the American Thyroid Association (ATA) pub-
lished treatment guidelines for patients with thyroid nodules
and DTC (10). Over the last decade, there have been many
advances in the diagnosis and therapy of both thyroid nodules
and DTC. Controversy exists in many areas, including the
most cost-effective approach in the diagnostic evaluation of a
thyroid nodule, the extent of surgery for small thyroid cancers,
the use of radioactive iodine to ablate remnant tissue following
thyroidectomy, the appropriate use of thyroxine suppression
therapy, and the role of human recombinant thyrotropin
(rhTSH). In recognition of the changes that have taken place in
the overall management of these clinically important prob-
lems, the ATA appointed a task force to re-examine the current
strategies that are used to diagnose and treat thyroid nodules
and DTC, and to develop clinical guidelines using principles of
evidence-based medicine. Members of the taskforce included
experts in thyroid nodule and thyroid cancer management
with representation from the fields of endocrinology, surgery,
and nuclear medicine. The medical opinions expressed here
are those of the authors; none were dictated by the ATA. The
final document was approved by the ATA Board of Directors
and endorsed (in alphabetical order) by the American Asso-
ciation of Clinical Endocrinologists (AACE), American College
of Endocrinology, British Association of Head and Neck
Oncologists (BAHNO), The Endocrine Society, European As-
sociation for Cranio-Maxillo-Facial Surgery (EACMFS), Eur-
opean Association of Nuclear Medicine (EANM), European
Society of Endocrine Surgeons (ESES), European Society for
Paediatric Endocrinology (ESPE), International Association of
Endocrine Surgeons (IAES), and Latin American Thyroid So-
ciety (LATS).
Other groups have previously developed guidelines, in-
cluding the American Association of Clinical Endocrinologists
and the American Association of Endocrine Surgeons (11), the
British Thyroid Association and The Royal College of Physi-
cians (12), and the National Comprehensive Cancer Network
(13) that have provided somewhat conflicting recommenda-
tions due to the lack of high quality evidence from random-
ized controlled trials. The European Thyroid Association has
published consensus guidelines for the management of DTC
(14). The European Association of Nuclear Medicine has also
recently published consensus guidelines for radioiodine (RAI)
therapy of DTC (15).
The ATA guidelines taskforce used a strategy similar to that
employed by the National Institutes of Health for its Consen-
sus Development Conferences (http:==consensus.nih.gov=
aboutcdp.htm), and developed a series of clinically relevant
questions pertaining to thyroid nodule and thyroid cancer di-
agnosis and treatment. These questions were as follows:
—Questions regarding thyroid nodules
 What is the appropriate evaluation of clinically or inci-
dentally discovered thyroid nodule(s)?
* What laboratory tests and imaging modalities are in-
dicated?
* What is the role of fine-needle aspiration (FNA)?
 What is the best method of long-term follow up of pa-
tients with thyroid nodules?
 What is the role of medical therapy of patients with
benign thyroid nodules?
 How should thyroid nodules in children and pregnant
women be managed?
—Questions regarding the initial management of DTC
 What is the role of preoperative staging with diagnostic
imaging and laboratory tests?
 What is the appropriate operation for indeterminate
thyroid nodules and DTC?
 What is the role of postoperative staging systems and
which should be used?
 What is the role of postoperative RAI remnant ablation?
 What is the role of thyrotropin (TSH) suppression
therapy?
 Is there a role for adjunctive external beam irradiation or
chemotherapy?
—Questions regarding the long term management of DTC
 What are the appropriate features of long-term man-
agement?
 What is the role of serum thyroglobulin (Tg) assays?
 What is the role of US and other imaging techniques
during follow-up?
 What is the role of TSH suppression in long-term follow-
up?
 What is the most appropriate management of patients
with metastatic disease?
 How should Tg-positive, scan-negative patients be
managed?
 What is the role of external radiation therapy?
 What is the role of chemotherapy?
— What are directions for future research?
The initial ATA guidelines were published in 2006 (16).
Because of the rapid growth of the literature on this topic,
plans for revising the guidelines within 24–36 months of
publication were made at the inception of the project. Re-
levant articles on thyroid cancer were identified using the
same search criteria employed for the original guidelines (16).
Individual task force members submitted suggestions for
clarification of prior recommendations, as well as new infor-
mation derived from studies published since 2004. Relevant
literature continued to be reviewed through December 2008.
To begin the revision process, a half-day meeting was held
on June 2, 2007. The Task Force was broadened to include
European experts and a head and neck surgeon. Three sub-
sequent half-day meetings were held on October 5, 2007; July
13, 2008; and October 5, 2008, to review these suggestions and
for additional comments to be considered. The meeting in July
2008 also included a meeting with six additional surgeons in
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Table 1. Organization of Management Guideline Recommendations, Tables, and Figures
for Patients with Thyroid Nodules and Differentiated Thyroid Cancer
Page Location keya Sections and subsections Itemb
1171 [A1] THYROID NODULE GUIDELINES T1
1171 [A2] Evaluation of Newly Discovered Thyroid Nodules F1
1171 [A3] Laboratory tests
1171 [A4] Serum TSH R1–R2
1171 [A5] Serum thyroglobulin (Tg) R3
1171 [A6] Serum calcitonin R4
1173 [A7] Role of fine-needle aspiration (FNA)
1173 [A8] Ultrasound (US) with FNA R5, T3
1174 [A9] Cytopathological interpretation of FNA samples
1174 [A10] Nondiagnostic cytology R6
1174 [A11] Cytology suggesting papillary thyroid cancer (PTC) R7
1174 [A12] Indeterminate cytology R8–R10
1175 [A13] Benign cytology R11
1175 [A14] Multinodular goiter (MNG)=multiple thyroid nodules R12–R13
1175 [A15] Long-Term Follow-Up of Thyroid Nodules R14–R15
1176 [A16] Medical therapy for benign thyroid nodules R16–R17
1176 [A17] Thyroid nodules in children R18
1176 [A18] Thyroid nodules in pregnant women R19–R20
1176 [B1] DIFFERENTIATED THYROID CANCER (DTC):
INITIAL MANAGEMENT GUIDELINES
1176 [B2] Goals of Initial Therapy of DTC
1177 [B3] Preoperative staging of DTC
1177 [B4] Neck imaging R21–R22
1177 [B5] Serum Tg R23
1177 [B6] Thyroid surgery
1178 [B7] Surgery for nondiagnostic biopsy R24–R25
1178 [B8] Surgery for biopsy diagnostic of malignancy R26
1179 [B9] Lymph node dissection R27–R28, F2
1180 [B10] Completion thyroidectomy R29–R30
1180 [B11] Postoperative staging systems
1180 [B12] Role of postoperative staging
1180 [B13] AJCC=UICC TNM staging R31, T4
1181 [B14] Role of postoperative remnant ablation R32, T5
1183 [B15] Preparation for radioiodine (RAI) remnant ablation R33, F3
1183 [B16] rhTSH preparation R34
1183 [B17] RAI scanning before RAI ablation R35
1185 [B18] Radiation doses for RAI ablation R36–R37
1185 [B19] Low-iodine diet for RAI ablation R38
1185 [B20] Post RAI ablation whole-body RAI scan R39
1185 [B21] Post Initial Therapy of DTC
1185 [B22] Role of TSH suppression therapy
1185 [B23] Degree of initial TSH suppression required R40
1186 [B24] Adjunctive measures
1186 [B25] External beam irradiation R41
1186 [B26] Chemotherapy R42
1186 [C1] DTC: LONG-TERM MANAGEMENT
1186 [C2] Appropriate Features of Long-Term Management
1186 [C3] Appropriate method of follow-up after surgery F4
1186 [C4] Criteria for absence of persistent tumor
1186 [C5] Role of serum Tg assays R43–R45
1189 [C6] Whole body RAI scans, US, and other imaging
aIf viewing these guidelines on the Web, or in a File, copy the Location Key to the Find or Search Function to navigate rapidly to the desired section.
bR, recommendation; T, table; F, figure.
(continued)
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Table 1. (Continued)
Page Location keya Sections and subsections Itemb
1189 [C7] Diagnostic whole-body RAI scans R46–R47
1189 [C8] Cervical ultrasound R48a–c
1189 [C9] FDG-PET Scanning R48d
1189 [C10] Role of thyroxine suppression of TSH R49
1190 [C11] Management of Metastatic Disease
1190 [C12] Surgery for locoregional metastases R50
1190 [C13] Surgery for aerodigestive invasion R51
1191 [C14] RAI for local or distant metastatic disease
1191 [C15] Methods for administering RAI R52–R54
1191 [C16] The use of lithium in RAI therapy R55
1191 [C17] Metastasis to various organs
1192 [C18] Pulmonary metastasis R56–R58
1192 [C19] Non–RAI-avid pulmonary disease R59
1193 [C20] Bone metastases R60–R64
1193 [C21] Brain metastases R65–R67
1194 [C22] Management of Complications of RAI Therapy R68–R70
1194 [C23] Secondary malignancies and leukemia from RAI R71
1194 [C24] Other risks to bone marrow from RAI R72
1194 [C25] Effects of RAI on gonads and in nursing women R73–R74
1195 [C26] Management of Tg Positive, RAI Scan–Negative Patients R75–R77, F5
1197 [C27] Patients with a negative post-treatment whole-body scan R78–R79
1197 [C28] External beam radiation for metastatic disease R80
1197 [D1] DIRECTIONS FOR FUTURE RESEARCH
1197 [D2] Novel Therapies and Clinical Trials
1197 [D3] Inhibitors of oncogenic signaling pathways
1197 [D4] Modulators of growth or apoptosis
1197 [D5] Angiogenesis inhibitors
1197 [D6] Immunomodulators
1197 [D7] Gene therapy
1198 [D8] Better Understanding of the Long-Term Risks of RAI
1198 [D9] Clinical Significance of Persistent Low-Level Tg
1198 [D10] The Problem of Tg Antibodies
1198 [D11] Small Cervical Lymph Node Metastases
1198 [D12] Improved Risk Stratification
Table 2. Strength of Panelists’ Recommendations Based on Available Evidence
Rating Definition
A Strongly recommends. The recommendation is based on good evidence that the service or intervention can improve
important health outcomes. Evidence includes consistent results from well-designed, well-conducted studies in
representative populations that directly assess effects on health outcomes.
B Recommends. The recommendation is based on fair evidence that the service or intervention can improve
important health outcomes. The evidence is sufficient to determine effects on health outcomes, but the strength
of the evidence is limited by the number, quality, or consistency of the individual studies; generalizability to
routine practice; or indirect nature of the evidence on health outcomes.
C Recommends. The recommendation is based on expert opinion.
D Recommends against. The recommendation is based on expert opinion.
E Recommends against. The recommendation is based on fair evidence that the service or intervention does not
improve important health outcomes or that harms outweigh benefits.
F Strongly recommends against. The recommendation is based on good evidence that the service or intervention
does not improve important health outcomes or that harms outweigh benefits.
I Recommends neither for nor against. The panel concludes that the evidence is insufficient to recommend for
or against providing the service or intervention because evidence is lacking that the service or intervention
improves important health outcomes, the evidence is of poor quality, or the evidence is conflicting. As a result, the
balance of benefits and harms cannot be determined.
Adapted from the U.S. Preventive Services Task Force, Agency for Healthcare Research and Quality (17).
an effort to produce guidelines related to central neck dis-
section that would be as authoritative as possible. The orga-
nization of management guideline recommendations is
shown in Table 1. It was agreed to continue to categorize the
published data and strength of recommendations using a
modified schema proposed by the U.S. Preventive Services
Task Force (17) (Table 2).
[A1] THYROID NODULE GUIDELINES
A thyroid nodule is a discrete lesion within the thyroid
gland that is radiologically distinct from the surrounding
thyroid parenchyma. Some palpable lesions may not corre-
spond to distinct radiologic abnormalities (18). Such abnor-
malities do not meet the strict definition for thyroid nodules.
Nonpalpable nodules detected on US or other anatomic im-
aging studies are termed incidentally discovered nodules or
‘‘incidentalomas.’’ Nonpalpable nodules have the same risk of
malignancy as palpable nodules with the same size (19).
Generally, only nodules >1 cm should be evaluated, since
they have a greater potential to be clinically significant can-
cers. Occasionally, there may be nodules <1 cm that require
evaluation because of suspicious US findings, associated
lymphadenopathy, a history of head and neck irradiation, or a
history of thyroid cancer in one or more first-degree relatives.
However, some nodules <1 cm lack these warning signs yet
eventually cause morbidity and mortality. These are rare and,
given unfavorable cost=benefit considerations, attempts to
diagnose and treat all small thyroid cancers in an effort to
prevent these rare outcomes would likely cause more harm
than good. Approximately 1–2% of people undergoing 2-
deoxy-2[18F]fluoro-d-glucose positron emission tomography
(18FDG-PET) imaging for other reasons have thyroid nodules
discovered incidentally. Since the risk of malignancy in these
18FDG-positive nodules is about 33% and the cancers may be
more aggressive (20), such lesions require prompt evaluation
(21–23). When seen, diffuse 18FDG uptake is likely related to
underlying autoimmune thyroiditis.
[A2] What is the appropriate evaluation of clinically
or incidentally discovered thyroid nodule(s)?
(See Fig. 1 for algorithm)
With the discovery of a thyroid nodule, a complete history
and physical examination focusing on the thyroid gland and
adjacent cervical lymph nodes should be performed. Pertinent
historical factors predicting malignancy include a history of
childhood head and neck irradiation, total body irradiation
for bone marrow transplantation (24), family history of thy-
roid carcinoma, or thyroid cancer syndrome (e.g., Cowden’s
syndrome, familial polyposis, Carney complex, multiple en-
docrine neoplasia [MEN] 2, Werner syndrome) in a first-
degree relative, exposure to ionizing radiation from fallout
in childhood or adolescence (25), and rapid growth and
hoarseness. Pertinent physical findings suggesting possible
malignancy include vocal cord paralysis, lateral cervical
lymphadenopathy, and fixation of the nodule to surrounding
tissues.
[A3] What laboratory tests and imaging modalities are
indicated?
[A4] Serum TSH with US and with or without scan. With
the discovery of a thyroid nodule >1 cm in any diameter or
diffuse or focal thyroidal uptake on 18FDG-PET scan, a se-
rum TSH level should be obtained. If the serum TSH is
subnormal, a radionuclide thyroid scan should be obtained
to document whether the nodule is hyperfunctioning (i.e.,
tracer uptake is greater than the surrounding normal thy-
roid), isofunctioning or ‘‘warm’’ (i.e., tracer uptake is equal to
the surrounding thyroid), or nonfunctioning (i.e., has uptake
less than the surrounding thyroid tissue). Since hyperfunc-
tioning nodules rarely harbor malignancy, if one is found
that corresponds to the nodule in question, no cytologic
evaluation is necessary. If overt or subclinical hyperthy-
roidism is present, additional evaluation is required. Higher
serum TSH, even within the upper part of the reference
range, is associated with increased risk of malignancy in a
thyroid nodule (26).
& RECOMMENDATION 1
Measure serum TSH in the initial evaluation of a patient
with a thyroid nodule. If the serum TSH is subnormal, a
radionuclide thyroid scan should be performed using either
technetium 99 mTc pertechnetate or 123I. Recommendation
rating: A
Diagnostic thyroid US should be performed in all
patients with a suspected thyroid nodule, nodular goiter, or
radiographic abnormality; e.g., a nodule found incidentally
on computed tomography (CT) or magnetic resonance im-
aging (MRI) or thyroidal uptake on 18FDG-PET scan.
Thyroid US can answer the following questions: Is there
truly a nodule that corresponds to the palpable abnormal-
ity? How large is the nodule? Does the nodule have benign
or suspicious features? Is suspicious cervical lymphade-
nopathy present? Is the nodule greater than 50% cystic? Is
the nodule located posteriorly in the thyroid gland? These
last two features might decrease the accuracy of FNA bi-
opsy performed with palpation (27,28). Also, there may
be other thyroid nodules present that require biopsy based
on their size and appearance (18,29,30). As already noted,
FNA is recommended especially when the serum TSH
is elevated because, compared with normal thyroid glands,
the rate of malignancy in nodules in thyroid glands
involved with Hashimoto’s thyroiditis is as least as high or
possibly higher (31,32).
& RECOMMENDATION 2
Thyroid sonography should be performed in all patients
with known or suspected thyroid nodules. Recommenda-
tion rating: A
[A5] Serum Tg measurement. Serum Tg levels can be ele-
vated in most thyroid diseases and are an insensitive and
nonspecific test for thyroid cancer (33).
& RECOMMENDATION 3
Routine measurement of serum Tg for initial evaluation of
thyroid nodules is not recommended. Recommendation
rating: F
[A6] Serum calcitonin measurement. The utility of serum
calcitonin has been evaluated in a series of prospective,
nonrandomized studies (34–37). The data suggest that the
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use of routine serum calcitonin for screening may detect
C-cell hyperplasia and medullary thyroid cancer at an
earlier stage and overall survival may be improved. How-
ever, most studies rely on pentagastrin stimulation test-
ing to increase specificity. This drug is no longer available
in the United States, and there remain unresolved issues
of sensitivity, specificity, assay performance and cost-
effectiveness. A recent cost-effectiveness analysis suggested
that calcitonin screening would be cost effective in the
United States (38). However, the prevalence estimates of
medullary thyroid cancer in this analysis included patients
with C-cell hyperplasia and micromedullary carcinoma,
123I or 99Tc Scana
Normal or High TSH History, Physical, TSH Low TSH 
Diagnostic US 
RESULTS of FNA 
Elevated 
TSH 





Nodule on US  
Do FNA 
(See R5a–c) 



























Consider 123I Scan  





WORKUP OF THYROID NODULE
DETECTED BY PALPATION OR IMAGING
FIG. 1. Algorithm for the evaluation of patients with one or more thyroid nodules.
aIf the scan does not show uniform distribution of tracer activity, ultrasound may be considered to assess for the presence
of a cystic component.
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which have an uncertain clinical significance. If the un-
stimulated serum calcitonin determination has been ob-
tained and the level is greater than 100 pg=mL, medullary
cancer is likely present (39).
& RECOMMENDATION 4
The panel cannot recommend either for or against the
routine measurement of serum calcitonin. Recommenda-
tion rating: I
[A7] What is the role of FNA biopsy? FNA is the most
accurate and cost-effective method for evaluating thyroid
nodules. Retrospective studies have reported lower rates of
both nondiagnostic and false-negative cytology specimens
from FNA procedures performed via US guidance compared
to palpation (40,41). Therefore, for nodules with a higher
likelihood of either a nondiagnostic cytology (>25–50% cystic
component) (28) or sampling error (difficult to palpate or
posteriorly located nodules), US-guided FNA is preferred (see
Table 3). If the diagnostic US confirms the presence of a pre-
dominantly solid nodule corresponding to what is palpated,
the FNA may be performed via palpation or US guidance.
Traditionally FNA biopsy results are divided into four cate-
gories: nondiagnostic, malignant (risk of malignancy at sur-
gery >95%), indeterminate or suspicious for neoplasm, and
benign. The recent National Cancer Institute Thyroid Fine-
Needle Aspiration State of the Science Conference proposed a
more expanded classification for FNA cytology that adds two
additional categories: suspicious for malignancy (risk of ma-
lignancy 50–75%) and follicular lesion of undetermined sig-
nificance (risk of malignancy 5–10%). The conference further
recommended that ‘‘neoplasm, either follicular or Hürthle cell
neoplasm’’ be substituted for ‘‘indeterminate’’ (risk of malig-
nancy 15–25%) (42).
[A8] US for FNA decision making (see Table 3). Various
sonographic characteristics of a thyroid nodule have been
associated with a higher likelihood of malignancy (43–48).
These include nodule hypoechogenicity compared to the
normal thyroid parenchyma, increased intranodular vascu-
larity, irregular infiltrative margins, the presence of micro-
calcifications, an absent halo, and a shape taller than the width
measured in the transverse dimension. With the exception of
suspicious cervical lymphadenopathy, which is a specific but
insensitive finding, no single sonographic feature or combi-
nations of features is adequately sensitive or specific to
identify all malignant nodules. However, certain features and
combination of features have high predictive value for ma-
lignancy. Furthermore, the most common sonographic ap-
pearances of papillary and follicular thyroid cancer differ. A
PTC is generally solid or predominantly solid and hy-
poechoic, often with infiltrative irregular margins and in-
creased nodular vascularity. Microcalcifications, if present,
are highly specific for PTC, but may be difficult to distinguish
from colloid. Conversely, follicular cancer is more often iso- to
hyperechoic and has a thick and irregular halo, but does not
have microcalcifications (49). Follicular cancers that are<2 cm
in diameter have not been shown to be associated with met-
astatic disease (50).
Certain sonographic appearances may also be highly pre-
dictive of a benign nodule. A pure cystic nodule, although rare
(<2% of all nodules), is highly unlikely to be malignant (47). In
addition, a spongiform appearance, defined as an aggregation
of multiple microcystic components in more than 50% of the
nodule volume, is 99.7% specific for identification of a benign
Table 3. Sonographic and Clinical Features of Thyroid Nodules and Recommendations for FNA
Nodule sonographic or clinical features Recommended nodule threshold size for FNA
High-risk historya
Nodule WITH suspicious sonographic featuresb >5 mm Recommendation A
Nodule WITHOUT suspicious sonographic featuresb >5 mm Recommendation I
Abnormal cervical lymph nodes Allc Recommendation A
Microcalcifications present in nodule 1 cm Recommendation B
Solid nodule
AND hypoechoic >1 cm Recommendation B
AND iso- or hyperechoic 1–1.5 cm Recommendation C
Mixed cystic–solid nodule
WITH any suspicious ultrasound featuresb 1.5–2.0 cm Recommendation B
WITHOUT suspicious ultrasound features 2.0 cm Recommendation C
Spongiform nodule 2.0 cmd Recommendation C
Purely cystic nodule FNA not indicatede Recommendation E
aHigh-risk history: History of thyroid cancer in one or more first degree relatives; history of external beam radiation as a child; exposure to
ionizing radiation in childhood or adolescence; prior hemithyroidectomy with discovery of thyroid cancer, 18FDG avidity on PET scanning;
MEN2=FMTC-associated RET protooncogene mutation, calcitonin>100 pg=mL. MEN, multiple endocrine neoplasia; FMTC, familial medullary
thyroid cancer.
bSuspicious features: microcalcifications; hypoechoic; increased nodular vascularity; infiltrative margins; taller than wide on transverse view.
cFNA cytology may be obtained from the abnormal lymph node in lieu of the thyroid nodule.
dSonographic monitoring without biopsy may be an acceptable alternative (see text) (48).
eUnless indicated as therapeutic modality (see text).
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thyroid nodule (48,51,52). In a recent study, only 1 of 360
malignant nodules demonstrated this appearance (48) and in
another report, a spongiform appearance had a negative pre-
dictive value for malignancy of 98.5% (52). Elastography is an
emerging and promising sonographic technique that requires
additional validation with prospective studies (53).
Routine FNA is not recommended for subcentimeter nod-
ules. However, the presence of a solid hypoechoic nodule with
microcalcifications is highly suggestive of PTC. Although most
micropapillary carcinomas may be incidental findings, a subset
may be more clinically relevant, especially those >5 mm in
diameter (54). These include nodules that have abnormal
lymph nodes detected clinically or with imaging at presenta-
tion (55,56). Therefore, after imaging a subcentimeter nodule
with a suspicious appearance, sonographic assessment of lat-
eral neck and central neck lymph nodes (more limited due to
the presence of the thyroid) must be performed. Detection of
abnormal lymph nodes should lead to FNA of the lymph node.
Other groups of patients for whom consideration of FNA of a
subcentimeter nodule may be warranted include those with a
higher likelihood of malignancy (high risk history): 1) family
history of PTC (57); 2) history of external beam radiation ex-
posure as a child (58); 3) exposure to ionizing radiation in
childhood or adolescence (59); 4) history of prior hemi-
thyroidectomy with discovery of thyroid cancer; and 5) 18FDG-
PET–positive thyroid nodules.
Mixed cystic–solid nodules and predominantly cystic with
>50% cystic component are generally evaluated by FNA with
directed biopsy of the solid component (especially the vas-
cular component.) Cyst drainage may also be performed, es-
pecially in symptomatic patients.
& RECOMMENDATION 5 (see Table 3)
(a) FNA is the procedure of choice in the evaluation of
thyroid nodules. Recommendation rating: A
(b) US guidance for FNA is recommended for those nod-
ules that are nonpalpable, predominantly cystic, or
located posteriorly in the thyroid lobe. Recommenda-
tion rating: B
[A9] What are the principles of the cytopathological inter-
pretation of FNA samples?
[A10] Nondiagnostic cytology. Nondiagnostic biopsies are
those that fail to meet specified criteria for cytologic adequacy
that have been previously established (the presence of at least
six follicular cell groups, each containing 10–15 cells derived
from at least two aspirates of a nodule) (5). After an initial
nondiagnostic cytology result, repeat FNA with US guidance
will yield a diagnostic cytology specimen in 75% of solid
nodules and 50% of cystic nodules (28). Therefore, such bi-
opsies need to be repeated using US guidance (60) and, if
available, on-site cytologic evaluation, which may substan-
tially increase cytology specimen adequacy (61,62). However,
up to 7% of nodules continue to yield nondiagnostic cytology
results despite repeated biopsies and may be malignant at the
time of surgery (63,64).
& RECOMMENDATION 6
(a) US guidance should be used when repeating the FNA
procedure for a nodule with an initial nondiagnostic
cytology result. Recommendation rating: A
(b) Partially cystic nodules that repeatedly yield non-
diagnostic aspirates need close observation or surgical
excision. Surgery should be more strongly considered
if the cytologically nondiagnostic nodule is solid. Re-
commendation rating: B
[A11] Cytology suggesting PTC.
& RECOMMENDATION 7
If a cytology result is diagnostic of or suspicious for PTC,
surgery is recommended (65). Recommendation rating: A
[A12] Indeterminate cytology (follicular or Hürthle cell neoplasm
follicular lesion of undetermined significance, atypia). Indetermi-
nate cytology, reported as ‘‘follicular neoplasm’’ or ‘‘Hürthle
cell neoplasm’’ can be found in 15–30% of FNA specimens (4)
and carries a 20–30% risk of malignancy (42), while lesions
reported as atypia or follicular lesion of undetermined signifi-
cance are variably reported and have 5–10% risk of malignancy
(42). While certain clinical features such as male sex and nodule
size (>4 cm) (66), older patient age (67), or cytologic features
such as presence of atypia (68) can improve the diagnostic ac-
curacy for malignancy in patients with indeterminate cytology,
overall predictive values are still low. Many molecular markers
(e.g., galectin-3 (69), cytokeratin, BRAF) have been evaluated to
improve diagnostic accuracy for indeterminate nodules (70–
72). Recent large prospective studies have confirmed the ability
of genetic markers (BRAF, Ras, RET=PTC) and protein markers
(galectin-3) to improve preoperative diagnostic accuary for
patients with indeterminate thyroid nodules (69,73,74). Many
of these markers are available for commercial use in reference
laboratories but have not yet been widely applied in clinical
practice. It is likely that some combination of molecular
markers will be used in the future to optimize management of
patients with indeterminate cytology on FNA specimens.
Recently, 18FDG-PET scanning has been utilized in an ef-
fort to distinguish those indeterminate nodules that are be-
nign from those that are malignant (75–78). 18FDG-PET scans
appear to have relatively high sensitivity for malignancy but
low specificity, but results vary among studies (79).
& RECOMMENDATION 8
(a) The use of molecular markers (e.g., BRAF, RAS,
RET=PTC, Pax8-PPARg, or galectin-3) may be consid-
ered for patients with indeterminate cytology on FNA
to help guide management. Recommendation rating: C
(b) The panel cannot recommend for or against routine
clinical use of 18FDG-PET scan to improve diagnostic
accuracy of indeterminate thyroid nodules. Recom-
mendation rating: I
& RECOMMENDATION 9
If the cytology reading reports a follicular neoplasm, a 123I
thyroid scan may be considered, if not already done, es-
pecially if the serum TSH is in the low-normal range. If a
concordant autonomously functioning nodule is not seen,
lobectomy or total thyroidectomy should be considered.
Recommendation rating: C
& RECOMMENDATION 10
If the reading is ‘‘suspicious for papillary carcinoma’’ or
‘‘Hürthle cell neoplasm,’’ a radionuclide scan is not needed,
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and either lobectomy or total thyroidectomy is re-
commended, depending on the lesion’s size and other risk
factors. Recommendation rating: A
[A13] Benign cytology.
& RECOMMENDATION 11
If the nodule is benign on cytology, further immediate di-
agnostic studies or treatment are not routinely required.
Recommendation rating: A
[A14] How should multinodular thyroid glands or multi-
nodular goiters be evaluated for malignancy? Patients with
multiple thyroid nodules have the same risk of malignancy as
those with solitary nodules (18,44). However, one large study
found that a solitary nodule had a higher likelihood of malig-
nancy than did a nonsolitary nodule ( p< 0.01), although the
risk of malignancy per patient was the same and independent
of the number of nodules (47). A diagnostic US should be
performed to delineate the nodules, but if only the ‘‘dominant’’
or largest nodule is aspirated, the thyroid cancer may be missed
(44). Radionuclide scanning should also be considered in pa-
tients with multiple thyroid nodules, if the serum TSH is in the
low or low-normal range, with FNA being reserved for those
nodules that are shown to be hypofunctioning.
& RECOMMENDATION 12
(a) In the presence of two or more thyroid nodules >1 cm,
those with a suspicious sonographic appearance (see
text and Table 3) should be aspirated preferentially.
Recommendation rating: B
(b) If none of the nodules has a suspicious sonographic
appearance and multiple sonographically similar coa-
lescent nodules with no intervening normal paren-
chyma are present, the likelihood of malignancy is low
and it is reasonable to aspirate the largest nodules only
and observe the others with serial US examinations.
Recommendation rating: C
& RECOMMENDATION 13
A low or low-normal serum TSH concentration may sug-
gest the presence of autonomous nodule(s). A technetium
99 mTc pertechnetate or 123I scan should be performed and
directly compared to the US images to determine func-
tionality of each nodule >1–1.5 cm. FNA should then be
considered only for those isofunctioning or nonfunctioning
nodules, among which those with suspicious sonographic
features should be aspirated preferentially. Recommenda-
tion rating: B
[A15] What are the best methods for long-term
follow-up of patients with thyroid nodules?
Thyroid nodules diagnosed as benign require follow-up
because of a low, but not negligible, false-negative rate of up
to 5% with FNA (41,80), which may be even higher with
nodules >4 cm (81). While benign nodules may decrease in
size, they often increase in size, albeit slowly (82). One study
of cytologically benign thyroid nodules <2 cm followed by
ultrasonography for about 38 months found that the rate of
thyroid nodule growth did not distinguish between benign
and malignant nodules (83).
Nodule growth is not in and of itself pathognomonic of
malignancy, but growth is an indication for repeat biopsy. For
mixed cystic–solid nodules, the indication for repeat biopsy
should be based upon growth of the solid component. For
nodules with benign cytologic results, recent series report
a higher false-negative rate with palpation FNA (1–3%)
(40,84,85) than with US FNA (0.6%) (40). Since the accuracy of
physical examination for nodule size is likely inferior to that of
US (30), it is recommended that serial US be used in follow-up
of thyroid nodules to detect clinically significant changes in
size. There is no consensus on the definition of nodule growth,
however, or the threshold that would require rebiopsy. Some
groups suggest a 15% increase in nodule volume, while others
recommend measuring a change in the mean nodule diameter
(82,86). One reasonable definition of growth is a 20% increase
in nodule diameter with a minimum increase in two or more
dimensions of at least 2 mm. This approximates the 50% in-
crease in nodule volume that was found by Brauer et al. (87) to
be the minimally significant reproducibly recorded change in
nodule size. These authors suggested that only volume
changes of at least 49% or more can be interpreted as nodule
shrinkage or growth and consequently suggest that future
investigations should not describe changes in nodule volume
<50% as significant. A 50% cutoff for nodule volume reduc-
tion or growth, which is used in many studies, appears to
appropriate and safe, since the false-negative rate for malig-
nant thyroid nodules on repeat FNA is low (88,89).
& RECOMMENDATION 14
(a) It is recommended that all benign thyroid nodules be
followed with serial US examinations 6–18 months
after the initial FNA. If nodule size is stable (i.e., no
more than a 50% change in volume or <20% increase
in at least two nodule dimensions in solid nodules or
in the solid portion of mixed cystic–solid nodules), the
interval before the next follow-up clinical examination
or US may be longer, e.g., every 3–5 years. Recom-
mendation rating: C
(b) If there is evidence for nodule growth either by palpation
or sonographically (more than a 50% change in volume or
a 20% increase in at least two nodule dimensions with
a minimal increase of 2 mm in solid nodules or in the
solid portion of mixed cystic–solid nodules), the FNA
should be repeated, preferably with US guidance. Re-
commendation rating: B
Cystic nodules that are cytologically benign can be moni-
tored for recurrence (fluid reaccumulation) which can be seen
in 60–90% of patients (90,91). For those patients with subse-
quent recurrent symptomatic cystic fluid accumulation,
surgical removal, generally by hemithyroidectomy, or per-
cutaneous ethanol injection (PEI) are both reasonable strate-
gies. Four controlled studies demonstrated a 75–85% success
rate after PEI compared with a 7–38% success rate in controls
treated by simple cyst evacuation or saline injection. Success
was achieved after an average of two PEI treatments. Com-
plications included mild to moderate local pain, flushing,
dizziness, and dysphonia (90–93).
& RECOMMENDATION 15
Recurrent cystic thyroid nodules with benign cytology
should be considered for surgical removal or PEI based on
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compressive symptoms and cosmetic concerns. Recom-
mendation rating: B
[A16] What is the role of medical therapy for benign thyroid
nodules? Evidence from multiple randomized control trials
and three meta-analyses suggest that thyroid hormone in doses
that suppress the serum TSH to subnormal levels may result in
a decrease in nodule size and may prevent the appearance of
new nodules in regions of the world with borderline low iodine
intake. Data in iodine-sufficient populations are less compel-
ling (94–96), with large studies suggesting that only about
17–25% of thyroid nodules shrink more than 50% with le-
vothyroxine (LT4) suppression of serum TSH (94–96).
& RECOMMENDATION 16
Routine suppression therapy of benign thyroid nodules in
iodine sufficient populations is not recommended. Re-
commendation rating: F
& RECOMMENDATION 17
Patients with growing nodules that are benign after repeat
biopsy should be considered for continued monitoring or
intervention with surgery based on symptoms and clinical
concern. There are no data on the use of LT4 in this sub-
population of patients. Recommendation rating: I
[A17] How should thyroid nodules in children be man-
aged? Thyroid nodules occur less frequently in children
than in adults. In one study in which approximately 5000
children aged 11–18 years were assessed annually in the
southwestern United States, palpable thyroid nodules oc-
curred in approximately 20 per 1000 children, with an annual
incidence of 7 new cases per 1000 children (97). Some studies
have shown the frequency of malignancy to be higher in
children than adults, in the range of 15–20% (98–100), whereas
other data have suggested that the frequency of thyroid can-
cer in childhood thyroid nodules is similar to that of adults
(101,102). FNA biopsy is sensitive and specific in the diagnosis
of childhood thyroid nodules (99–101).
& RECOMMENDATION 18
The diagnostic and therapeutic approach to one or more
thyroid nodules in a child should be the same as it would be
in an adult (clinical evaluation, serum TSH, US, FNA).
Recommendation rating: A
[A18] How should thyroid nodules in pregnant women be
managed? It is uncertain if thyroid nodules discovered in
pregnant women are more likely to be malignant than those
found in nonpregnant women (103), since there are no popu-
lation-based studies on this question. The evaluation is the same
as for a nonpregnant patient, with the exception that a radio-
nuclide scan is contraindicated. In addition, for patients with
nodules diagnosed as DTC by FNA during pregnancy, delay-
ing surgery until after delivery does not affect outcome (104).
& RECOMMENDATION 19
For euthyroid and hypothyroid pregnant women with
thyroid nodules, FNA should be performed. For women
with suppressed serum TSH levels that persist after the first
trimester, FNA may be deferred until after pregnancy and
cessation of lactation, when a radionuclide scan can be
performed to evaluate nodule function. Recommendation
rating: A
If the FNA cytology is consistent with PTC, surgery is re-
commended. However, there is no consensus about whether
surgery should be performed during pregnancy or after de-
livery. To minimize the risk of miscarriage, surgery during
pregnancy should be done in the second trimester before
24 weeks gestation (105). However, PTC discovered during
pregnancy does not behave more aggressively than that di-
agnosed in a similar-aged group of nonpregnant women
(104,106). A retrospective study of pregnant women with DTC
found there to be no difference in either recurrence, or survival
rates, between women operated on during or after their
pregnancy (104). Further, retrospective data suggest that
treatment delays of less than 1 year from the time of thyroid
cancer discovery do not adversely affect patient outcome (107).
Finally, a recent study reported a higher rate of complications
in pregnant women undergoing thyroid surgery compared
with nonpregnant women (108). Some experts recommend
thyroid hormone suppression therapy for pregnant women
with FNA suspicious for or diagnostic of PTC, if surgery is
deferred until the postpartum period (109).
& RECOMMENDATION 20
(a) A nodule with cytology indicating PTC discovered early
in pregnancy should be monitored sonographically and
if it grows substantially (as defined above) by 24 weeks
gestation, surgery should be performed at that point.
However, if it remains stable by midgestation or if it is
diagnosed in the second half of pregnancy, surgery may
be performed after delivery. In patients with more ad-
vanced disease, surgery in the second trimester is rea-
sonable. Recommendation rating: C
(b) In pregnant women with FNA that is suspicious for or
diagnostic of PTC, consideration could be given to
administration of LT4 therapy to keep the TSH in the
range of 0.1–1 mU=L. Recommendation rating: C
[B1] DIFFERENTIATED THYROID CANCER:
INITIAL MANAGEMENT GUIDELINES
Differentiated thyroid cancer, arising from thyroid follicular
epithelial cells, accounts for the vast majority of thyroid can-
cers. Of the differentiated cancers, papillary cancer comprises
about 85% of cases compared to about 10% that have follicular
histology, and 3% that are Hürthle cell or oxyphil tumors (110).
In general, stage for stage, the prognoses of PTC and follicular
cancer are similar (107,110). Certain histologic subtypes of PTC
have a worse prognosis (tall cell variant, columnar cell variant,
diffuse sclerosing variant), as do more highly invasive variants
of follicular cancer. These are characterized by extensive vas-
cular invasion and invasion into extrathyroidal tissues or
extensive tumor necrosis and=or mitoses. Other poorly dif-
ferentiated aggressive tumor histologies include trabecular,
insular, and solid subtypes (111). In contrast, minimally in-
vasive follicular thyroid cancer, is characterized histologically
by microscopic penetration of the tumor capsule without
vascular invasion, and carries no excess mortality (112–115).
[B2] Goals of initial therapy of DTC
The goals of initial therapy of DTC are follows:
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1. To remove the primary tumor, disease that has ex-
tended beyond the thyroid capsule, and involved cer-
vical lymph nodes. Completeness of surgical resection
is an important determinant of outcome, while residual
metastatic lymph nodes represent the most common
site of disease persistence=recurrence (116–118).
2. To minimize treatment-related morbidity. The extent of
surgery and the experience of the surgeon both play
important roles in determining the risk of surgical
complications (119,120).
3. To permit accurate staging of the disease. Because dis-
ease staging can assist with initial prognostication,
disease management, and follow-up strategies, accurate
postoperative staging is a crucial element in the man-
agement of patients with DTC (121,122).
4. To facilitate postoperative treatment with radioactive
iodine, where appropriate. For patients undergoing RAI
remnant ablation, or RAI treatment of residual or met-
astatic disease, removal of all normal thyroid tissue is
an important element of initial surgery (123). Near total
or total thyroidectomy also may reduce the risk for re-
currence within the contralateral lobe (124).
5. To permit accurate long-term surveillance for disease
recurrence. Both RAI whole-body scanning (WBS) and
measurement of serum Tg are affected by residual
normal thyroid tissue. Where these approaches are
utilized for long-term monitoring, near-total or total-
thyroidectomy is required (125).
6. To minimize the risk of disease recurrence and meta-
static spread. Adequate surgery is the most important
treatment variable influencing prognosis, while radio-
active iodine treatment, TSH suppression, and external
beam irradiation each play adjunctive roles in at least
some patients (125–128).
[B3] What is the role of preoperative staging with diag-
nostic imaging and laboratory tests?
[B4] Neck imaging. Differentiated thyroid carcinoma
(particularly papillary carcinoma) involves cervical lymph
nodes in 20–50% of patients in most series using standard
pathologic techniques (45,129–132), and may be present even
when the primary tumor is small and intrathyroidal (133). The
frequency of micrometastases may approach 90%, depending
on the sensitivity of the detection method (134,135). However,
the clinical implications of micrometastases are likely less
significant compared to macrometastases. Preoperative US
identifies suspicious cervical adenopathy in 20–31% of cases,
potentially altering the surgical approach (136,137) in as many
as 20% of patients (138,139). However, preoperative US
identifies only half of the lymph nodes found at surgery, due
to the presence of the overlying thyroid gland (140).
Sonographic features suggestive of abnormal metastatic
lymph nodes include loss of the fatty hilus, a rounded rather
than oval shape, hypoechogenicity, cystic change, calcifica-
tions, and peripheral vascularity. No single sonographic fea-
ture is adequately sensitive for detection of lymph nodes with
metastatic thyroid cancer. A recent study correlated the sono-
graphic features acquired 4 days preoperatively directly with
the histology of 56 cervical lymph nodes. Some of the most
specific criteria were short axis>5 mm (96%), presence of cystic
areas (100%), presence of hyperechogenic punctuations re-
presenting either colloid or microcalcifications (100%), and
peripheral vascularity (82%). Of these, the only one with suf-
ficient sensitivity was peripheral vascularity (86%). All of the
others had sensitivities <60% and would not be adequate to
use as single criterion for identification of malignant involve-
ment (140). As shown by earlier studies (141,142), the feature
with the highest sensitivity was absence of a hilus (100%), but
this had a low specificity of only 29%. The location of the lymph
nodes may also be useful for decision-making. Malignant
lymph nodes are much more likely to occur in levels III, IV,
and VI than in level II (140,142). Figure 2 illustrates the delin-
eation of cervical lymph node Levels I through VI.
Confirmation of malignancy in lymph nodes with a sus-
picious sonographic appearance is achieved by US-guided
FNA aspiration for cytology and=or measurement of Tg in the
needle washout. This FNA measurement of Tg is valid even in
patients with circulating Tg autoantibodies (143,144).
Accurate staging is important in determining the prognosis
and tailoring treatment for patients with DTC. However,
unlike many tumor types, the presence of metastatic disease
does not obviate the need for surgical excision of the primary
tumor in DTC (145). Because metastatic disease may respond
to RAI therapy, removal of the thyroid as well as the primary
tumor and accessible locoregional disease remains an im-
portant component of initial treatment even in metastatic
disease.
As US evaluation is uniquely operator dependent, alter-
native imaging procedures may be preferable in some clinical
settings, though the sensitivities of CT, MRI, and PET for the
detection of cervical lymph node metastases are all relatively
low (30–40%) (146). These alternative imaging modalities, as
well as laryngoscopy and endoscopy, may also be useful in
the assessment of large, rapidly growing, or retrosternal or
invasive tumors to assess the involvement of extrathyroidal
tissues (147,148).
& RECOMMENDATION 21
Preoperative neck US for the contralateral lobe and cervical
(central and especially lateral neck compartments) lymph
nodes is recommended for all patients undergoing thy-
roidectomy for malignant cytologic findings on biopsy. US-
guided FNA of sonographically suspicious lymph nodes
should be performed to confirm malignancy if this would
change management. Recommendation rating: B
& RECOMMENDATION 22
Routine preoperative use of other imaging studies (CT,
MRI, PET) is not recommended. Recommendation rating: E
[B5] Measurement of serum Tg. There is limited evidence
that high preoperative concentrations of serum Tg may pre-
dict a higher sensitivity for postoperative surveillance with
serum Tg (149). Evidence that this impacts patient manage-
ment or outcomes is not yet available.
& RECOMMENDATION 23
Routine preoperative measurement of serum Tg is not re-
commended. Recommendation rating: E
[B6] What is the appropriate operation for indeterminate
thyroid nodules and DTC? The goals of thyroid surgery
can include provision of a diagnosis after a nondiagnostic or
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indeterminate biopsy, removal of the thyroid cancer, staging,
and preparation for radioactive ablation and serum Tg moni-
toring. Surgical options to address the primary tumor should
be limited to hemithyroidectomy with or without isthmu-
sectomy, near-total thyroidectomy (removal of all grossly vis-
ible thyroid tissue, leaving only a small amount [<1 g] of tissue
adjacent to the recurrent laryngeal nerve near the ligament of
Berry), and total thyroidectomy (removal of all grossly visible
thyroid tissue). Subtotal thyroidectomy, leaving >1 g of tissue
with the posterior capsule on the uninvolved side, is an inap-
propriate operation for thyroid cancer (150).
[B7] Surgery for a nondiagnostic biopsy, a biopsy suspicious for
papillary cancer or suggestive of ‘‘follicular neoplasm’’ (including
special consideration for patients with other risk factors). Amongst
solitary thyroid nodules with an indeterminate (‘‘follicular
neoplasm’’ or Hürthle cell neoplasm) biopsy, the risk of
malignancy is approximately 20% (151–153). The risk is
higher with large tumors (>4 cm), when atypical features
(e.g., cellular pleomorphism) are seen on biopsy, when the
biopsy reading is ‘‘suspicious for papillary carcinoma,’’ in
patients with a family history of thyroid carcinoma, and in
patients with a history of radiation exposure (66,154,155). For
solitary nodules that are repeatedly nondiagnostic on biopsy,
the risk of malignancy is unknown but is probably closer to 5–
10% (63).
& RECOMMENDATION 24
For patients with an isolated indeterminate solitary nodule
who prefer a more limited surgical procedure, thyroid lo-
bectomy is the recommended initial surgical approach.
Recommendation rating: C
& RECOMMENDATION 25
(a) Because of an increased risk for malignancy, total
thyroidectomy is indicated in patients with indeter-
minate nodules who have large tumors (>4 cm), when
marked atypia is seen on biopsy, when the biopsy
reading is ‘‘suspicious for papillary carcinoma,’’ in
patients with a family history of thyroid carcinoma,
and in patients with a history of radiation exposure.
Recommendation rating: A
(b) Patients with indeterminate nodules who have bilat-
eral nodular disease, or those who prefer to undergo
bilateral thyroidectomy to avoid the possibility of re-
quiring a future surgery on the contralateral lobe,
should also undergo total or near-total thyroidectomy.
Recommendation rating: C
[B8] Surgery for a biopsy diagnostic for malignancy. Near-
total or total thyroidectomy is recommended if the primary



















FIG. 2. Lymph node compartments separated into levels and sublevels. Level VI contains the thyroid gland, and the
adjacent nodes bordered superiorly by the hyoid bone, inferiorly by the innominate (brachiocephalic) artery, and laterally on
each side by the carotid sheaths. The level II, III, and IV nodes are arrayed along the jugular veins on each side, bordered
anteromedially by level VI and laterally by the posterior border of the sternocleidomastoid muscle. The level III nodes are
bounded superiorly by the level of the hyoid bone, and inferiorly by the cricoid cartilage; levels II and IV are above and below
level III, respectively. The level I node compartment includes the submental and submandibular nodes, above the hyoid bone,
and anterior to the posterior edge of the submandibular gland. Finally, the level V nodes are in the posterior triangle, lateral
to the lateral edge of the sternocleidomastoid muscle. Levels I, II, and V can be further subdivided as noted in the figure. The
inferior extent of level VI is defined as the suprasternal notch. Many authors also include the pretracheal and paratracheal
superior mediastinal lymph nodes above the level of the innominate artery (sometimes referred to as level VII) in central neck
dissection (166).
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thyroid nodules present or regional or distant metastases are
present, the patient has a personal history of radiation therapy
to the head and neck, or the patient has first-degree family
history of DTC. Older age (>45 years) may also be a criterion
for recommending near-total or total thyroidectomy even
with tumors <1–1.5 cm, because of higher recurrence rates in
this age group (112,116,122,123,157). Increased extent of pri-
mary surgery may improve survival for high-risk patients
(158–160) and low-risk patients (156). A study of over 50,000
patients with PTC found on multivariate analysis that total
thyroidectomy significantly improved recurrence and sur-
vival rates for tumors >1.0 cm (156). When examined sepa-
rately, even patients with 1.0–2.0 cm tumors who underwent
lobectomy, had a 24% higher risk of recurrence and a 49%
higher risk of thyroid cancer mortality ( p¼ 0.04 and p< 0.04,
respectively). Other studies have also shown that rates of re-
currence are reduced by total or near total thyroidectomy
among low-risk patients (122,161,162).
& RECOMMENDATION 26
For patients with thyroid cancer >1 cm, the initial surgical
procedure should be a near-total or total thyroidectomy
unless there are contraindications to this surgery. Thyroid
lobectomy alone may be sufficient treatment for small
(<1 cm), low-risk, unifocal, intrathyroidal papillary carci-
nomas in the absence of prior head and neck irradiation or
radiologically or clinically involved cervical nodal metas-
tases. Recommendation rating: A
[B9] Lymph node dissection. Regional lymph node metas-
tases are present at the time of diagnosis in 20–90% of patients
with papillary carcinoma and a lesser proportion of patients
with other histotypes (129,139). Although PTC lymph node
metastases are reported by some to have no clinically impor-
tant effect on outcome in low risk patients, a study of the
Surveillance, Epidemiology, and End Results (SEER) database
found, among 9904 patients with PTC, that lymph node me-
tastases, age>45 years, distant metastasis, and large tumor size
significantly predicted poor outcome on multivariate analysis
(163). All-cause survival at 14 years was 82% for PTC without
lymph node and 79% with lymph node metastases ( p< 0.05).
Another recent SEER registry study concluded that cervical
lymph node metastases conferred an independent risk of de-
creased survival, but only in patients with follicular cancer and
patients with papillary cancer over age 45 years (164). Also, the
risk of regional recurrence is higher in patients with lymph
node metastases, especially in those patients with multiple
metastases and=or extracapsular nodal extension (165).
In many patients, lymph node metastases in the central
compartment (166) do not appear abnormal preoperatively
with imaging (138) or by inspection at the time of surgery.
Central compartment dissection (therapeutic or prophylactic)
can be achieved with low morbidity in experienced hands
(167–171), and may convert some patients from clinical N0 to
pathologic N1a, upstaging patients over age 45 from Ameri-
can Joint Committee on Cancer (AJCC) stage I to III (172). A
recent consensus conference statement discusses the relevant
anatomy of the central neck compartment, delineates the no-
dal subgroups within the central compartment commonly
involved with thyroid cancer, and defines the terminology
relevant to central compartment neck dissection (173).
Comprehensive bilateral central compartment node dis-
section may improve survival compared to historic controls
and reduce risk for nodal recurrence (174). In addition, se-
lective unilateral paratracheal central compartment node
dissection increases the proportion of patients who appear
disease free with unmeasureable Tg levels 6 months after
surgery (175). Other studies of central compartment dissec-
tion have demonstrated higher morbidity, primarily recurrent
laryngeal nerve injury and transient hypoparathyroidism,
with no reduction in recurrence (176,177). In another study,
comprehensive (bilateral) central compartment dissection
demonstrated higher rates of transient hypoparathyroidism
compared to selective (unilateral) dissection with no reduc-
tion in rates of undetectable or low Tg levels (178). Although
some lymph node metastases may be treated with radioactive
iodine, several treatments may be necessary, depending upon
the histology, size, and number of metastases (179).
& RECOMMENDATION 27*
(a) Therapeutic central-compartment (level VI) neck dis-
section for patients with clinically involved central or
lateral neck lymph nodes should accompany total
thyroidectomy to provide clearance of disease from the
central neck. Recommendation rating: B
(b) Prophylactic central-compartment neck dissection
(ipsilateral or bilateral) may be performed in patients
with papillary thyroid carcinoma with clinically unin-
volved central neck lymph nodes, especially for ad-
vanced primary tumors (T3 or T4). Recommendation
rating: C
(c) Near-total or total thyroidectomy without prophylactic
central neck dissection may be appropriate for small
(T1 or T2), noninvasive, clinically node-negative PTCs
and most follicular cancer. Recommendation rating: C
These recommendations (R27a–c) should be interpreted in
light of available surgical expertise. For patients with small,
noninvasive, apparently node-negative tumors, the balance of
risk and benefit may favor simple near-total thyroidectomy
with close intraoperative inspection of the central compart-
ment with compartmental dissection only in the presence of
obviously involved lymph nodes. This approach may increase
the chance of future locoregional recurrence, but overall this
approach may be safer in less experienced surgical hands.
Lymph nodes in the lateral neck (compartments II–V), level
VII (anterior mediastinum), and rarely in Level I may also be
involved by thyroid cancer (129,180). For those patients in
whom nodal disease is evident clinically, on preoperative US
and nodal FNA or Tg measurement, or at the time of surgery,
surgical resection may reduce the risk of recurrence and
possibly mortality (56,139,181). Functional compartmental
*R27a, 27b, 27c, and 28 were developed in collaboration with an ad hoc committee of endocrinologists (David S. Cooper, M.D., Richard T.
Kloos, M.D., Susan J. Mandel, M.D., M.P.H., and R. Michael Tuttle, M.D.), otolaryngology-head and neck surgeons (Gregory Randolph, M.D.,
David Steward, M.D., David Terris, M.D. and Ralph Tufano, M.D.), and endocrine surgeons (Sally Carty, M.D., Gerard M. Doherty, M.D.,
Quan-Yang Duh, M.D., and Robert Udelsman, M.D., M.B.A.)
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en-bloc neck dissection is favored over isolated lymphade-
nectomy (‘‘berry picking’’) with limited data suggesting im-
proved mortality (118,182–184).
& RECOMMENDATION 28*
Therapeutic lateral neck compartmental lymph node dis-
section should be performed for patients with biopsy-
proven metastatic lateral cervical lymphadenopathy.
Recommendation rating: B
[B10] Completion thyroidectomy. Completion thyroidec-
tomy may be necessary when the diagnosis of malignancy is
made following lobectomy for an indeterminate or non-
diagnostic biopsy. Some patients with malignancy may re-
quire completion thyroidectomy to provide complete
resection of multicentric disease (185), and to allow RAI
therapy. Most (186,187) but not all (185) studies of papillary
cancer have observed a higher rate of cancer in the opposite
lobe when multifocal (two or more foci), as opposed to uni-
focal, disease is present in the ipsilateral lobe. The surgical
risks of two-stage thyroidectomy (lobectomy followed by
completion thyroidectomy) are similar to those of a near-total
or total thyroidectomy (188).
& RECOMMENDATION 29
Completion thyroidectomy should be offered to those pa-
tients for whom a near-total or total thyroidectomy would
have been recommended had the diagnosis been available
before the initial surgery. This includes all patients with
thyroid cancer except those with small (<1 cm), unifocal,
intrathyroidal, node-negative, low-risk tumors. Ther-
apeutic central neck lymph node dissection should be in-
cluded if the lymph nodes are clinically involved.
Recommendation rating: B
& RECOMMENDATION 30
Ablation of the remaining lobe with radioactive iodine has
been used as an alternative to completion thyroidectomy
(189). It is unknown whether this approach results in sim-
ilar long-term outcomes. Consequently, routine radioactive
iodine ablation in lieu of completion thyroidectomy is not
recommended. Recommendation rating: D
[B11] What is the role of postoperative staging systems
and which should be used?
[B12] The role of postoperative staging. Postoperative stag-
ing for thyroid cancer, as for other cancer types, is used: 1) to
permit prognostication for an individual patient with DTC;
2) to tailor decisions regarding postoperative adjunctive ther-
apy, including RAI therapy and TSH suppression, to assess the
patient’s risk for disease recurrence and mortality; 3) to make
decisions regarding the frequency and intensity of follow-up,
directing more intensive follow-up towards patients at highest
risk; and 4) to enable accurate communication regarding a
patient among health care professionals. Staging systems also
allow evaluation of differing therapeutic strategies applied to
comparable groups of patients in clinical studies.
[B13] AJCC=UICC TNM staging. Application of the
AJCC=International Union against Cancer (AJCC=UICC)
classification system based on pTNM parameters and age is
recommended for tumors of all types, including thyroid
cancer (121,190), because it provides a useful shorthand
method to describe the extent of the tumor (191) (Table 4). This
classification is also used for hospital cancer registries and
epidemiologic studies. In thyroid cancer, the AJCC=UICC
stage does not take account of several additional independent
prognostic variables and may risk misclassification of some
patients. Numerous other schemes have been developed in an
effort to achieve more accurate risk factor stratification, in-
cluding CAEORTC, AGES, AMES, U of C, MACIS, OSU,
MSKCC, and NTCTCS systems. (107,116,122,159,192–195).
These schemes take into account a number of factors identi-
fied as prognostic for outcome in multivariate analysis of
retrospective studies, with the most predictive factors gener-
ally being regarded as the presence of distant metastases, the
age of the patient, and the extent of the tumor. These and other
risk factors are weighted differently among these systems
according to their importance in predicting outcome, but no
scheme has demonstrated clear superiority (195). Each of the
schemes allows accurate identification of the majority (70–
85%) of patients at low-risk of mortality (T1–3, M0 patients),
allowing the follow-up and management of these patients to
be less intensive than the higher-risk minority (T4 and M1
patients), who may benefit from a more aggressive manage-
ment strategy (195). Nonetheless, none of the examined
staging classifications is able to account for more than a small
proportion of the uncertainty in either short-term, disease-
specific mortality or the likelihood of remaining disease free
(121,195,196). AJCC=IUCC staging was developed to predict
risk for death, not recurrence. For assessment of risk of re-
currence, a three-level stratification can be used:
 Low-risk patients have the following characteristics:
1) no local or distant metastases; 2) all macroscopic tu-
mor has been resected; 3) there is no tumor invasion of
locoregional tissues or structures; 4) the tumor does not
have aggressive histology (e.g., tall cell, insular, colum-
nar cell carcinoma) or vascular invasion; 5) and, if 131I is
given, there is no 131I uptake outside the thyroid bed on
the first posttreatment whole-body RAI scan (RxWBS)
(197–199).
 Intermediate-risk patients have any of the following:
1) microscopic invasion of tumor into the perithyroidal
soft tissues at initial surgery; 2) cervical lymph node
metastases or 131I uptake outside the thyroid bed on the
RxWBS done after thyroid remnant ablation (200,201);
or 3) tumor with aggressive histology or vascular inva-
sion (202–204).
 High-risk patients have 1) macroscopic tumor invasion,
2) incomplete tumor resection, 3) distant metastases, and
possibly 4) thyroglobulinemia out of proportion to what
is seen on the posttreatment scan (205).
Since initial staging is based on clinico-pathologic factors
that are available shortly after diagnosis and initial therapy,
the AJCC stage of the patient does not change over time.
*See footnote, page 1179.
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However, depending on the clinical course of the disease and
response to therapy, the risk of recurrence and the risk of
death may change over time. Appropriate management re-
quires an ongoing reassessment of the risk of recurrence and
the risk of disease-specific mortality as new data are obtained
during follow-up (206).
& RECOMMENDATION 31
Because of its utility in predicting disease mortality, and
its requirement for cancer registries, AJCC=UICC staging
is recommended for all patients with DTC. The use of
postoperative clinico-pathologic staging systems is also re-
commended to improve prognostication and to plan
follow-up for patients with DTC. Recommendation rating: B
[B14] What is the role of postoperative RAI remnant
ablation? Postoperative RAI remnant ablation is increas-
ingly being used to eliminate the postsurgical thyroid rem-
nant (122). Ablation of the small amount of residual normal
thyroid remaining after total thyroidectomy may facilitate the
early detection of recurrence based on serum Tg measurement
and=or RAI WBS. Additionally, the posttherapy scan ob-
tained at the time of remnant ablation may facilitate initial
staging by identifying previously undiagnosed disease, es-
pecially in the lateral neck. Furthermore, from a theoretical
point of view, this first dose of RAI may also be considered
adjuvant therapy because of the potential tumoricidal effect on
persistent thyroid cancer cells remaining after appropriate
surgery in patients at risk for recurrence or disease specific
mortality. Depending on the risk stratification of the indi-
vidual patient, the primary goal of the first dose of RAI after
total thyroidectomy may be 1) remnant ablation (to facilitate
detection of recurrent disease and initial staging), 2) adjuvant
therapy (to decrease risk of recurrence and disease specific
mortality by destroying suspected, but unproven metastatic
disease), or 3) RAI therapy (to treat known persistent disease).
While these three goals are closely interrelated, a clearer un-
derstanding of the specific indications for treatment will im-
prove our ability to select patients most likely to benefit from
RAI after total thyroidectomy, and will also influence our
recommendations regarding choice of administered activity
for individual patients. Supporting the use of RAI as adju-
vant therapy, a number of large, retrospective studies show a
significant reduction in the rates of disease recurrence
Table 4. TNM Classification System for Differentiated Thyroid Carcinoma
Definition
T1 Tumor diameter 2 cm or smaller
T2 Primary tumor diameter >2 to 4 cm
T3 Primary tumor diameter >4 cm limited to the thyroid or with minimal extrathyroidal extension
T4a Tumor of any size extending beyond the thyroid capsule to invade subcutaneous soft tissues, larynx, trachea,
esophagus, or recurrent laryngeal nerve
T4b Tumor invades prevertebral fascia or encases carotid artery or mediastinal vessels
TX Primary tumor size unknown, but without extrathyroidal invasion
N0 No metastatic nodes
N1a Metastases to level VI (pretracheal, paratracheal, and prelaryngeal=Delphian lymph nodes)
N1b Metastasis to unilateral, bilateral, contralateral cervical or superior mediastinal nodes
NX Nodes not assessed at surgery
M0 No distant metastases
M1 Distant metastases
MX Distant metastases not assessed
Stages
Patient age <45 years Patient age 45 years or older
Stage I Any T, any N, M0 T1, N0, M0
Stage II Any T, any N, M1 T2, N0, M0










Stage IVB T4b, Any N, M0
Stage IVC Any T, Any N, M1
Used with the permission of the American Joint Committee on Cancer (AJCC), Chicago, Illinois.
The original source for this material is the AJCC Cancer Staging Manual, Sixth Edition (435).
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(107,159,160,207) and cause-specific mortality (159,160,207–
209). However, other similar studies show no such benefit, at
least among the majority of patients with PTC, who are at the
lowest risk for mortality (110,122,162,209–212). In those
studies that show benefit, the advantage appears to be re-
stricted to patients with tumors >1.5 cm, or with residual
disease following surgery, while lower-risk patients do not
show evidence for benefit (122,159,213). The National Thyroid
Cancer Treatment Cooperative Study Group (NTCTCSG) re-
port (214) of 2936 patients found after a median follow-up of 3
years, that near-total thyroidectomy followed by RAI therapy
and aggressive thyroid hormone suppression therapy pre-
dicted improved overall survival of patients with NTCTCSG
stage III and IV disease, and was also beneficial for patients
with NTCTCSG stage II disease. No impact of therapy was
observed in patients with stage I disease. It should be noted
that the NTCTCSG staging criteria are similar but not iden-
tical to the AJCC criteria. Thus, older patients with micro-
scopic extrathyroidal extension are stage II in the NTCTCSG
system, but are stage III in the AJCC system. There are recent
data suggesting a benefit of RAI in patients with more
aggressive histologies (215). There are no prospective ran-
domized trials that have addressed this question (209). Un-
fortunately, many clinical circumstances have not been
examined with regard to the efficacy of RAI ablative therapy.
Table 5 presents a framework for deciding whether RAI is
worthwhile, solely based on the AJCC classification, and
provides the rationale for therapy and the strength of existing
evidence for or against treatment.
In addition to the major factors listed in Table 5, several
other histological features may place the patient at higher risk
of local recurrence or metastases than would have been pre-
dicted by the AJCC staging system. These include worrisome
histologic subtypes (such as tall cell, columnar, insular, and
solid variants, as well as poorly differentiated thyroid cancer),
the presence of intrathyroidal vascular invasion, or the find-
ing of gross or microscopic multifocal disease. While many of
these features have been associated with increased risk, there
are inadequate data to determine whether RAI ablation has a
benefit based on specific histologic findings, independent of
tumor size, lymph node status, and the age of the patient.
Therefore, while RAI ablation is not recommended for all
patients with these higher risk histologic features, the pres-
ence of these features in combination with size of the tumor,
lymph node status, and patient age may increase the risk of
recurrence or metastatic spread to a degree that is high en-
ough to warrant RAI ablation in selected patients. However,
in the absence of data for most of these factors, clinical judg-
ment must prevail in the decision-making process. For mi-
croscopic multifocal papillary cancer, when all foci are<1 cm,
recent data suggest that RAI is of no benefit in preventing
recurrence (216,217).
Nonpapillary histologies (such as follicular thyroid cancer
and Hürthle cell cancer) are generally regarded as higher risk
tumors. Expert opinion supports the use of RAI in almost all
of these cases. However, because of the excellent prognosis
associated with surgical resection alone in small follicular
thyroid cancers manifesting only capsular invasion (without
vascular invasion (so-called ‘‘minimally invasive follicular
cancer’’), RAI ablation may not be required for all patients
with this histological diagnosis (112).
& RECOMMENDATION 32
(a) RAI ablation is recommended for all patients with
known distant metastases, gross extrathyroidal exten-
sion of the tumor regardless of tumor size, or primary
tumor size >4 cm even in the absence of other higher
risk features (see Table 5 for strength of evidence).
(b) RAI ablation is recommended for selected patients
with 1–4 cm thyroid cancers confined to the thyroid,


















T1 1 cm or less, intrathyroidal or
microscopic multifocal
No No Yes No E
1–2 cm, intrathyroidal No Conflicting dataa Yes Selective usea I
T2 >2–4 cm, intrathyroidal No Conflicting dataa Yes Selective usea C
T3 >4 cm
<45 years old No Conflicting dataa Yes Yes B
45 years old Yes Yes Yes Yes B
Any size, any age, minimal
extrathyroidal extension
No Inadequate dataa Yes Selective usea I
T4 Any size with gross
extrathyroidal extension
Yes Yes Yes Yes B
Nx,N0 No metastatic nodes documented No No Yes No I
N1 <45 years old No Conflicting dataa Yes Selective usea C
>45 years old Conflicting data Conflicting dataa Yes Selective usea C
M1 Distant metastasis present Yes Yes Yes Yes A
aBecause of either conflicting or inadequate data, we cannot recommend either for or against RAI ablation for this entire subgroup.
However, selected patients within this subgroup with higher risk features may benefit from RAI ablation (see modifying factors in the text).
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who have documented lymph node metastases, or
other higher risk features (see preceding paragraphs)
when the combination of age, tumor size, lymph node
status, and individual histology predicts an interme-
diate to high risk of recurrence or death from thyroid
cancer (see Table 5 for strength of evidence for indi-
vidual features). Recommendation rating: C (for se-
lective use in higher risk patients)
(c) RAI ablation is not recommended for patients with
unifocal cancer <1 cm without other higher risk fea-
tures (see preceding paragraphs). Recommendation
rating: E
(d) RAI ablation is not recommended for patients with
multifocal cancer when all foci are <1 cm in the ab-
sence other higher risk features (see preceding para-
graphs). Recommendation rating: E
[B15] How should patients be prepared for RAI ablation?
(see Fig. 3) Remnant ablation requires TSH stimulation. No
controlled studies have been performed to assess adequate
levels of endogenous TSH for optimal ablation therapy or
follow-up testing. Noncontrolled studies suggest that a TSH
of >30 mU=L is associated with increased RAI uptake in
tumors (218), while studies using single dose exogenous TSH
suggest maximal thyrocyte stimulation at TSH levels between
51 and 82 mU=L (219, 220). However, the total area under the
TSH curve, and not simply the peak serum TSH concentra-
tion, is also potentially important for optimal RAI uptake by
thyroid follicular cells. Endogenous TSH elevation can be
achieved by two basic approaches to thyroid hormone with-
drawal, stopping LT4 and switching to LT3 for 2–4 weeks
followed by withdrawal of LT3 for 2 weeks, or discontinua-
tion of LT4 for 3 weeks without use of LT3. Both methods of
preparation can achieve serum TSH levels >30 mU=L in
>90% of patients (220–229). These two approaches have not
been directly compared for efficiency of patient prepara-
tion (efficacy of ablation, iodine uptake, Tg levels, disease
detection), although a recent prospective study showed no
difference in hypothyroid symptoms between these two ap-
proaches (230). Other preparative methods have been pro-
posed, but have not been validated by other investigators
(231,232). Children with thyroid cancer achieve adequate
TSH elevation within 14 days of LT4 withdrawal (233). A low
serum Tg level at the time of ablation has excellent negative
predictive value for absence of residual disease, and the risk
of persistent disease increases with higher stimulated Tg
levels (198,205,234).
& RECOMMENDATION 33
Patients undergoing RAI therapy or diagnostic testing can
be prepared by LT4 withdrawal for at least 2–3 weeks or
LT3 treatment for 2–4 weeks and LT3 withdrawal for 2
weeks with measurement of serum TSH to determine
timing of testing or therapy (TSH >30 mU=L). Thyroxine
therapy (with or without LT3 for 7–10 days) may be re-
sumed on the second or third day after RAI administration.
Recommendation rating: B
[B16] Can rhTSH (Thyrogen) be used in lieu of thyroxine
withdrawal for remnant ablation? For most patients, including
those unable to tolerate hypothyroidism or unable to generate
an elevated TSH, remnant ablation can be achieved with
rhTSH (235,236). A prospective randomized study found that
thyroid hormone withdrawal and rhTSH stimulation were
equally effective in preparing patients for 131I remnant abla-
tion with 100 mCi with significantly improved quality of life
(237). Another randomized study using rhTSH showed that
ablation rates were comparable with 50 mCi compared to
100 mCi with a significant decrease (33%) in whole-body ir-
radiation (238). Finally, a recent study has shown that ablation
rates were similar with either withdrawal or preparation with
rhTSH using 50 mCi of 131I (239). In addition, short-term re-
currence rates have been found to be similar in patients pre-
pared with thyroid hormone withdrawal or rhTSH (240).
Recombinant human TSH is approved for remnant ablation in
the United States, Europe, and many other countries around
the world.
& RECOMMENDATION 34
Remnant ablation can be performed following thyroxine
withdrawal or rhTSH stimulation. Recommendation rat-
ing: A
[B17] Should RAI scanning be performed before RAI abla-
tion? RAI WBS provides information on the presence of io-
dine-avid thyroid tissue, which may represent the normal
thyroid remnant or the presence of residual disease in the
postoperative setting. In the presence of a large thyroid rem-
nant, the scan is dominated by uptake within the remnant,
potentially masking the presence of extrathyroidal disease
within locoregional lymph nodes, the upper mediastinum, or
even at distant sites, reducing the sensitivity of disease de-
tection (241). Furthermore, there is an increasing trend to avoid
pretherapy RAI scans altogether because of its low impact
on the decision to ablate, and because of concerns over 131I-
induced stunning of normal thyroid remnants (242) and dis-
tant metastases from thyroid cancer (243). Stunning is defined
as a reduction in uptake of the 131I therapy dose induced by a
pretreatment diagnostic activity. Stunning occurs most
prominently with higher activities (5–10 mCi) of 131I (244),
with increasing time between the diagnostic dose and therapy
(245), and does not occur if the treatment dose is given within
72 hours of the scanning dose (246). However, the accuracy of
low-activity 131I scans has been questioned, and some research
has reported quantitatively the presence of stunning below the
threshold of visual detection (247). Although comparison
studies show excellent concordance between 123I and 131I for
tumor detection, optimal 123I activity and time to scan after 123I
administration are not known (248). Furthermore, 123I is ex-
pensive, is not universally available, its short half life (t½¼ 13
hours) makes handling this isotope logistically more difficult
(249), and stunning may also occur though to a lesser degree
than with 131I (245). Furthermore, a recent study showed no
difference in ablation rates between patients that had pre-
therapy scans with 123I (81%) compared to those who had
received diagnostic scans using 2 mCi of 131I (74%, p> 0.05)
(250). Alternatively, determination of the thyroid bed uptake,
without scanning, can be achieved using 10–100mCi 131I.
& RECOMMENDATION 35
Pretherapy scans and=or measurement of thyroid bed up-
take may be useful when the extent of the thyroid remnant
cannot be accurately ascertained from the surgical report
or neck ultrasonography, or when the results would alter
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ALGORITHM FOR REMNANT ABLATION: 
Initial Follow-Up in Patients with Differentiated Thyroid
Carcinoma in Whom Remnant Ablation is Indicated
One to Three Months after Surgery
Uptake Only in 
Thyroid Bedi
Final Surgery is a Total or Near-Total Thyroidectomy 
Completion  
Thyroidectomy 
Prior to Ablation 
(R29, R30) 






Neck USb, CT scan 
Serum Tgc
Consider PET Scan 




Diagnostic WBS Using 
rhTSH or THWf









5–8 Days Post 131I 
rhTSH or THW 






6–12 Months with 
TSH-Stimulated 
DxWBS, Tg 







FIG. 3. Algorithm for initial follow-up of patients with differentiated thyroid carcinoma.
aEBRT, external beam radiotherapy. The usual indication for EBRT is macroscopic unresectable tumor in a patient older
than 45 years; it is not usually recommended for children and adults less than age 45.
bNeck ultrasonography of operated cervical compartments is often compromised for several months after surgery.
cTg, thyroglobulin with anti-thyroglobulin antibody measurement; serum Tg is usually measured by immunometric assay
and may be falsely elevated for several weeks by injury from surgery or by heterophile antibodies, although a very high
serum Tg level after surgery usually indicates residual disease.
dSome clinicians suspect residual disease when malignant lymph nodes, or tumors with aggressive histologies (as defined
in the text) have been resected, or when there is a microscopically positive margin of resection.
erhTSH is recombinant human TSH and is administered as follows: 0.9 mg rhTSH i.m. on two consecutive days, followed
by 131I therapy on the third day.
fTHW is levothyroxine and=or triiodothyronine withdrawal.
gSee text for exceptions regarding remnant ablation. The smallest amount of 131I necessary to ablate normal thyroid
remnant tissue should be used. DxWBS (diagnostic whole-body scintigraphy) is not usually necessary at this point, but may
be performed if the outcome will change the decision to treat with radioiodine and=or the amount of administered activity.
hRxWBS is posttreatment whole-body scan done 5 to 8 days after therapeutic 131I administration.
iUptake in the thyroid bed may indicate normal remnant tissue or residual central neck nodal metastases.
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either the decision to treat or the activity of RAI that is
administered. If performed, pretherapy scans should uti-
lize 123I (1.5–3 mCi) or low-activity 131I (1–3 mCi), with the
therapeutic activity optimally administered within 72
hours of the diagnostic activity. Recommendation rating: C
[B18] What activity of 131I should be used for remnant
ablation? Successful remnant ablation is usually defined as
an absence of visible RAI uptake on a subsequent diagnostic
RAI scan or an undetectable stimulated serum Tg. Activities
between 30 and 100 mCi of 131I generally show similar rates of
successful remnant ablation (251–254) and recurrence rates
(213). Although there is a trend toward higher ablation rates
with higher activities (255,256), a recent prospective ran-
domized study found no significant difference in the remnant
ablation rate using 30 or 100 mCi of 131I (257). Furthermore,
there are data showing that 30 mCi is effective in ablating the
remnant with rhTSH preparation (258). In pediatric patients,
it is preferable to adjust the ablation activity according to the
patient’s body weight (259) or surface area (260).
& RECOMMENDATION 36
The minimum activity (30–100 mCi) necessary to achieve
successful remnant ablation should be utilized, particularly
for low-risk patients. Recommendation rating: B
& RECOMMENDATION 37
If residual microscopic disease is suspected or documented,
or if there is a more aggressive tumor histology (e.g., tall
cell, insular, columnar cell carcinoma), then higher activi-
ties (100–200 mCi) may be appropriate. Recommendation
rating: C
[B19] Is a low-iodine diet necessary before remnant
ablation? The efficacy of radioactive iodine depends on the
radiation dose delivered to the thyroid tissue (261). Low-
iodine diets (<50 mg=d of dietary iodine) and simple recom-
mendations to avoid iodine contamination have been
recommended prior to RAI therapy (261–263) to increase the
effective radiation dose. A history of possible iodine exposure
(e.g., intravenous contrast, amiodarone use) should be
sought. Measurement of iodine excretion with a spot urinary
iodine determination may be a useful way to identify patients
whose iodine intake could interfere with RAI remnant abla-
tion (263). Information about low-iodine diets can be obtained
at the Thyroid Cancer Survivors Association website (www.
thyca.org).
& RECOMMENDATION 38
A low-iodine diet for 1–2 weeks is recommended for pa-
tients undergoing RAI remnant ablation, particularly for
those patients with high iodine intake. Recommendation
rating: B
[B20] Should a posttherapy scan be performed following
remnant ablation? Posttherapy whole-body iodine scanning
is typically conducted approximately 1 week after RAI ther-
apy to visualize metastases. Additional metastatic foci have
been reported in 10–26% of patients scanned following high-
dose RAI treatment compared with the diagnostic scan
(264,265). The new abnormal uptake was found most often in
the neck, lungs, and mediastinum, and the newly discovered
disease altered the disease stage in approximately 10% of the
patients, affecting clinical management in 9–15% (264–266).
Iodine 131 single photon emission computed tomography
(SPECT)=CT fusion imaging may provide superior lesion lo-
calization after remnant ablation, but it is still a relatively new
imaging modality (267).
& RECOMMENDATION 39
A posttherapy scan is recommended following RAI rem-
nant ablation. This is typically done 2–10 days after the
therapeutic dose is administered, although published data
supporting this time interval are lacking. Recommendation
rating: B
[B21] Postsurgery and RAI therapy
early management of DTC
[B22] What is the role of TSH suppression therapy? DTC
expresses the TSH receptor on the cell membrane and re-
sponds to TSH stimulation by increasing the expression of
several thyroid specific proteins (Tg, sodium-iodide sym-
porter) and by increasing the rates of cell growth (268). Sup-
pression of TSH, using supra-physiologic doses of LT4, is used
commonly to treat patients with thyroid cancer in an effort to
decrease the risk of recurrence (127,214,269). A meta-analysis
supported the efficacy of TSH suppression therapy in pre-
venting major adverse clinical events (RR¼ 0.73; CI¼ 0.60–
0.88; p< 0.05) (269).
[B23] What is the appropriate degree of initial TSH
suppression? Retrospective and prospective studies have
demonstrated that TSH suppression to below 0.1 mU=L may
improve outcomes in high-risk thyroid cancer patients
(127,270), though no such evidence of benefit has been docu-
mented in low-risk patients. A prospective cohort study (214)
of 2936 patients found that overall survival improved signifi-
cantly when the TSH was suppressed to undetectable levels in
patients with NTCTCSG stage III or IV disease and suppressed
to the subnormal to undetectable range in patients with
NTCTCSG stage II disease; however, in the latter group there
was no incremental benefit from suppressing TSH to unde-
tectable levels. Suppression of TSH was not beneficial in pa-
tients with stage I disease. In another study, there was a
positive association between serum TSH levels and the risk for
recurrent disease and cancer-related mortality (271). Adverse
effects of TSH suppression may include the known conse-
quences of subclinical thyrotoxicosis, including exacerbation of
angina in patients with ischemic heart disease, increased risk
for atrial fibrillation in older patients (272), and increased risk of
osteoporosis in postmenopausal women (273).
& RECOMMENDATION 40
Initial TSH suppression to below 0.1 mU=L is re-
commended for high-risk and intermediate-risk thyroid
cancer patients, while maintenance of the TSH at or slightly
below the lower limit of normal (0.1–0.5 mU=L) is appro-
priate for low-risk patients. Similar recommendations ap-
ply to low-risk patients who have not undergone remnant
ablation, i.e., serum TSH 0.1–0.5 mU=L. Recommendation
rating: B
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[B24] Is there a role for adjunctive external beam irradiation
or chemotherapy?
[B25] External beam irradiation. External beam irradiation
is used infrequently in the management of thyroid cancer
except as a palliative treatment for locally advanced, other-
wise unresectable disease (274). There are reports of responses
among patients with locally advanced disease (275,276) and
improved relapse-free and cause-specific survival in patients
over age 60 with extrathyroidal extension but no gross re-
sidual disease (277). It remains unknown whether external
beam radiation might reduce the risk for recurrence in the
neck following adequate primary surgery and=or RAI treat-
ment in patients with aggressive histologic subtypes (278).
& RECOMMENDATION 41
The use of external beam irradiation to treat the primary
tumor should be considered in patients over age 45 with
grossly visible extrathyroidal extension at the time of sur-
gery and a high likelihood of microscopic residual disease,
and for those patients with gross residual tumor in whom
further surgery or RAI would likely be ineffective. The se-
quence of external beam irradiation and RAI therapy de-
pends on the volume of gross residual disease and the
likelihood of the tumor being RAI responsive. Re-
commendation rating: B
[B26] Chemotherapy. There are no data to support the use
of adjunctive chemotherapy in the management of DTC.
Doxorubicin may act as a radiation sensitizer in some tumors
of thyroid origin (279), and could be considered for patients
with locally advanced disease undergoing external beam ra-
diation.
& RECOMMENDATION 42
There is no role for the routine adjunctive use of chemo-
therapy in patients with DTC. Recommendation rating: F
[C1] DTC: LONG-TERM MANAGEMENT GUIDELINES
[C2] What are the appropriate features
of long-term management?
Accurate surveillance for possible recurrence in patients
thought to be free of disease is a major goal of long-term
follow-up. Tests with high negative predictive value allow
identification of patients unlikely to experience disease re-
currence, so that less aggressive management strategies can
be used that may be more cost effective and safe. Similarly,
patients with a higher risk of recurrence are monitored more
aggressively because it is believed that early detection of re-
current disease offers the best opportunity for effective
treatment. A large study (280), found that the residual life
span in disease-free patients treated with total or near-total
thyroidectomy and 131I for remnant ablation and, in some
cases, high dose 131I for residual disease, was similar to that in
the general Dutch population. In contrast, the life expectancy
for patients with persistent disease was reduced to 60% of that
in the general population but varied widely depending upon
tumor features. Age was not a factor in disease-specific mor-
tality when patients were compared with aged matched in-
dividuals in the Dutch population. Treatment thus appears
safe and does not shorten life expectancy. Although an in-
creased incidence of second tumors in thyroid cancer patients
has been recognized (157,281) this elevated risk was not found
to be associated with the use of 131I in another study (282), and
RAI therapy in low-risk patients did not affect median overall
survival in another (210). Patients with persistent or recurrent
disease are offered treatment to cure or to delay future mor-
bidity or mortality. In the absence of such options, therapies to
palliate by substantially reducing tumor burden or prevent-
ing tumor growth are utilized, with special attention paid to
tumors threatening critical structures.
A second goal of long-term follow-up is to monitor thy-
roxine suppression or replacement therapy, to avoid under-
replacement or overly aggressive therapy (283).
[C3] What is the appropriate method
for following patients after surgery
with or without remnant ablation?
See Fig. 4 for an algorithm for the first 6–12 months of
management.
[C4] What are the criteria for absence of persistent
tumor? In patients who have undergone total or near-total
thyroidectomy and thyroid remnant ablation, disease-free
status comprises all of the following:
1) no clinical evidence of tumor,
2) no imaging evidence of tumor (no uptake outside the
thyroid bed on the initial posttreatment WBS, or, if
uptake outside the thyroid bed had been present, no
imaging evidence of tumor on a recent diagnostic scan
and neck US), and
3) undetectable serum Tg levels during TSH suppression
and stimulation in the absence of interfering antibodies.
[C5] What is the role of serum Tg assays in the follow up of
DTC? Measurement of serum Tg levels is an important
modality to monitor patients for residual or recurrent disease.
Most laboratories currently use immunometric assays to
measure serum Tg, and it is important that these assays are
calibrated against the CRM-457 international standard. De-
spite improvements in standardization of thyroglobuin as-
says, there is still a twofold difference between some assays
(149), leading to the recommendation that measurements in
individual patients over time be performed in the same assay.
Immunometric assays are prone to interference from Tg
autoantibodies, which commonly cause falsely low serum
Tg measurements. Radioimmunoassays may be less prone
to antibody interference, but are not as widely available,
and their role in the clinical care of patients is uncertain. In
the absence of antibody interference, serum Tg has a high
degree of sensitivity and specificity to detect thyroid cancer,
especially after total thyroidectomy and remnant ablation,
with the highest degrees of sensitivity noted following thyroid
hormone withdrawal or stimulation using rhTSH (284). Serum
Tg measurements obtained during thyroid hormone sup-
pression of TSH, and, less commonly during TSH stimula-
tion, may fail to identify patients with relatively small amounts
of residual tumor (197,285,286). Conversely, even TSH-
stimulated Tg measurement may fail to identify patients with
clinically significant tumor, due to anti-Tg antibodies or less
commonly to defective or absent production and secretion of
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ALGORITHM for MANAGEMENT of DTC
SIX to TWELVE MONTHS after REMNANT ABLATION 
Tg (R43) and Neck US (R48a) 
While on T4
US Suspicious for Lymph 
Nodes or Nodules >5–8 mm  
US  
Negative  
Biopsy for Cytology  
and Tg Wash (R48b/c) 
If Negative, Monitor Positive Tg <1a,  
Tg Ab Neg 







(R45b and R48a) 
See Text 
Tg >1 ,b
Tg Ab Neg 
Tg <1,
Tg Ab Pos   
Consider  
Diagnostic  
RAI WBS (R47) 
Follow  
Tg Abd

























Neck US (R77) 
Consider Surgery, 131I Therapy, EBRT, 
Clinical Trial, or Tyrosine Kinase Inhibitor Therapy (R59b, 78b)
FIG. 4. Longer term follow-up of patients with differentiated thyroid carcinoma.
aTgAb is anti-thyroglobulin antibody usually measured by immunometric assay.
bHeterophile antibodies may be a cause of falsely elevated serum Tg levels (436,437). The use of heterophile blocking tubes
or heterophile blocking reagents have reduced, but not completely eliminated this problem. Tg that rises with TSH stimu-
lation and falls with TSH suppression is unlikely to result from heterophile antibodies.
cSee text concerning further information regarding levels of Tg at which therapy should be considered.
dTg radioimmunoassay (RIA) may be falsely elevated or suppressed by TgAb. Tg results following TSH stimulation with
rhTSH or thyroid hormone withdrawal are invalidated by TgAb in the serum even when Tg is measured by most RIA tests.
TgAb levels often decline to undetectable levels over years following surgery (306). A rising level of TgAb may be an early
indication of recurrent disease (305).
eSee text for decision regarding surgery versus medical therapy, and surgical approaches to locoregional metastases. FNA
confirmation of malignancy is generally advised. Preoperative chest CT is recommended as distant metastases may change
management.
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immunoreactive Tg by tumor cells (286). Tg levels should be
interpreted in light of the pretest probability of clinically sig-
nificant residual tumor. An aggressive or poorly differentiated
tumor may be present despite low basal or stimulated Tg; in
contrast, a minimally elevated stimulated Tg may occur in
patients at low risk for clinically significant morbidity (287).
Nevertheless, a single rhTSH-stimulated serum Tg<0.5 ng=mL
in the absence of anti-Tg antibody has an approximately
98–99.5% likelihood of identifying patients completely free of
tumor on follow-up (288,289).
Follow-up of low-risk patients who have undergone total
or near-total thyroidectomy alone without 131I remnant ab-
lation or hemithyroidectomy alone may represent a chal-
lenge. A cohort of 80 consecutive patients with very low-risk
papillary thyroid microcarcinoma who had undergone near-
total thyroidectomy without postoperative RAI treatment
was studied over 5 years (290). The rhTSH-stimulated serum
Tg levels were 1 ng=mL in 45 patients (56%) and >1 ng=mL
in 35 (44%) patients in whom rhTSH-stimulated Tg levels
were as high as 25 ng=mL. The diagnostic WBS (DxWBS)
revealed uptake in the thyroid bed but showed no patho-
logical uptake in any patient, and thyroid bed uptake corre-
lated with the rhTSH-stimulated serum Tg levels ( p< 0.0001).
Neck ultrasonography identified lymph node metastases
in both Tg-positive and Tg-negative patients. The authors
concluded that for follow-up of this group of patients: 1)
WBS was ineffective in detecting metastases; 2) neck ultra-
sonography as the main surveillance tool was highly sensitive
in detecting node metastases; and 3) detectable rhTSH-
stimulated serum Tg levels mainly depended upon the size of
thyroid remnants.
Initial follow-up for low-risk patients (about 85% of post-
operative patients) who have undergone total or near-total
thyroidectomy and 131I remnant ablation should be based
mainly on TSH-suppressed Tg and cervical US, followed
by TSH-stimulated serum Tg measurements if the TSH-
suppressed Tg testing is undetectable (197,285). However, a
Tg assay with a functional sensitivity of 0.1 ng=mL may re-
duce the need to perform TSH-stimulated Tg measurements
during the initial follow-up of some patients. In one study of
this assay, a T4-suppressed serum Tg <0.1 ng=mL was only
rarely (2.5%) associated with an rhTSH-stimulated Tg
>2 ng=mL; however, 61.5% of the patients had baseline Tg
elevation>0.1 ng=mL, but only one patient was found to have
residual tumor (291). In another study of the same assay (292),
a TSH-suppressed serum Tg level was >0.1 ng=mL in 14% of
patients, but the false-positive rate was 35% using an rhTSH-
stimulated Tg cutoff of >2 ng=mL, raising the possibility of
unnecessary testing and treatment. The only prospective
study also documented increased sensitivity of detection of
disease at the expense of reduced specificity (293).
Approximately 20% of patients who are clinically free of
disease with serum Tg levels <1 ng=mL during thyroid hor-
mone suppression of TSH (285) will have a serum Tg level
>2 ng=mL after rhTSH or thyroid hormone withdrawal at 12
months after initial therapy with surgery and RAI. In this pa-
tient population, one third will have identification of persistent
or recurrent disease and of increasing Tg levels, and the other
two thirds will remain free of clinical disease and will have
stable or decreasing stimulated serum Tg levels over time (294).
There is good evidence that a Tg cutoff level above 2 ng=mL
following rhTSH stimulation is highly sensitive in identifying
patients with persistent tumor (285,295–300). However, the
results of serum Tg measurements made on the same serum
specimen differ among assay methods (149). Therefore, the Tg
cutoff may differ significantly among medical centers and
laboratories. Further, the clinical significance of minimally
detectable Tg levels is unclear, especially if only detected fol-
lowing TSH stimulation. In these patients, the trend in serum
Tg over time will typically identify patients with clinically
significant residual disease. A rising unstimulated or stimu-
lated serum Tg indicates disease that is likely to become clini-
cally apparent (294,301).
The presence of anti-Tg antibodies, which occur in ap-
proximately 25% of thyroid cancer patients (302) and 10% of
the general population (303), will falsely lower serum Tg de-
terminations in immunometric assays (304). The use of re-
covery assays in this setting to detect significant interference is
controversial (201,304). Serial serum anti-Tg antibody quan-
tification using the same methodology may serve as an im-
precise surrogate marker of residual normal thyroid tissue or
tumor (305, 306).
& RECOMMENDATION 43
Serum Tg should be measured every 6–12 months by an
immunometric assay that is calibrated against the CRM-
457 standard. Ideally, serum Tg should be assessed in the
same laboratory and using the same assay, during follow-
up of patients with DTC who have undergone total or near
total thyroidectomy with or without thyroid remnant ab-
lation. Thyroglobulin antibodies should be quantitatively
assessed with every measurement of serum Tg. Recom-
mendation rating: A
& RECOMMENDATION 44
Periodic serum Tg measurements and neck ultrasonography
should be considered during follow-up of patients with DTC
who have undergone less than total thyroidectomy, and in
patients who have had a total thyroidectomy but not RAI
ablation. While specific cutoff levels during TSH suppres-
sion or stimulation that optimally distinguish normal re-
sidual thyroid tissue from persistent thyroid cancer are
unknown, rising Tg values over time are suspicious for
growing thyroid tissue or cancer. Recommendation rating: B
& RECOMMENDATION 45
(a) In low-risk patients who have had remnant ablation and
negative cervical US and undetectable TSH-suppressed
Tg within the first year after treatment, serum Tg should
be measured after thyroxine withdrawal or rhTSH stim-
ulation approximately 12 months after the ablation to
verify absence of disease. Recommendation rating: A
The timing or necessity of subsequent stimulated testing is
uncertain for those found to be free of disease, because there is
infrequent benefit in this patient cohort from repeated TSH-
stimulated Tg testing (289).
(b) Low-risk patients who have had remnant abla-
tion, negative cervical US, and undetectable TSH-
stimulated Tg can be followed primarily with yearly
clinical examination and Tg measurements on thyroid
hormone replacement. Recommendation rating: B
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[C6] What are the roles of diagnostic whole-body RAI scans,
US, and other imaging techniques during follow-up of DTC?
[C7] Diagnostic whole-body RAI scans. There are two main
issues that affect the use of DxWBS during follow-up: stun-
ning (described above) and accuracy. A DxWBS is most useful
during follow-up when there is little or no remaining normal
thyroid tissue. Disease not visualized on the DxWBS,
regardless of the activity of 131I employed, may occasionally
be visualized on the RxWBS images done after larger, thera-
peutic amounts of 131I (285,307–310). Following RAI ablation,
when the posttherapy scan does not reveal uptake outside the
thyroid bed, subsequent DxWBS have low sensitivity and are
usually not necessary in low-risk patients who are clinically
free of residual tumor and have an undetectable serum Tg
level on thyroid hormone and negative cervical US
(197,285,309,311).
& RECOMMENDATION 46
After the first RxWBS performed following RAI remnant
ablation, low-risk patients with an undetectable Tg on
thyroid hormone with negative antithyrogolublin anti-
bodies and a negative US do not require routine DxWBS
during follow-up. Recommendation rating: F
& RECOMMENDATION 47
DxWBS, either following thyroid hormone withdrawal
or rhTSH, 6–12 months after remnant ablation may be of
value in the follow-up of patients with high or intermedi-
ate risk of persistent disease (see risk stratification system
under AJCC=UICC TNM staging), but should be done
with 123I or low activity 131I. Recommendation rating: C
[C8] Cervical ultrasonography. Cervical ultrasonography is
highly sensitive in the detection of cervical metastases in pa-
tients with DTC (139,290,312). Recent data suggest that
measurement of Tg in the needle washout fluid enhances the
sensitivity of FNA of cervical nodes that are suspicious on US
(313,314). Cervical metastases occasionally may be detected
by neck ultrasonography even when TSH-stimulated serum
Tg levels remain undetectable (201,296).
& RECOMMENDATION 48
(a) Following surgery, cervical US to evaluate the thyroid
bed and central and lateral cervical nodal compartments
should be performed at 6–12 months and then periodi-
cally, depending on the patient’s risk for recurrent dis-
ease and Tg status. Recommendation rating: B
(b) If a positive result would change management, ultra-
sonographically suspicious lymph nodes greater than
5–8 mm in the smallest diameter should be biopsied for
cytology with Tg measurement in the needle washout
fluid. Recommendation rating: A
(c) Suspicious lymph nodes less than 5–8 mm in largest di-
ameter may be followed without biopsy with consider-
ation for intervention if there is growth or if the node
threatens vital structures. Recommendation rating: C
[C9] 18FDG-PET scanning. For many years, the primary
clinical application of 18FDG-PET scanning in thyroid cancer
was to localize disease in Tg-positive (>10 ng=mL), RAI scan–
negative patients (315). When used for this indication, insur-
ance providers have usually required documentation that the
patient had a follicular derived thyroid cancer with sup-
pressed or stimulated Tg >10 ng=mL in the setting of a neg-
ative DxWBS. Still, the impact of 18FDG-PET imaging on
biochemical cure, survival, or progression-free survival in this
setting are not well defined.
More recently, publications provide data that support the
use of 18FDG-PET scanning for indications beyond simple
disease localization in Tg-positive, RAI scan–negative pa-
tients (315,316).
Current additional clinical uses of 18FDG-PET scanning
may include:
 Initial staging and follow-up of high-risk patients with
poorly differentiated thyroid cancers unlikely to con-
centrate RAI in order to identify sites of disease that may
be missed with RAI scanning and conventional imaging.
 Initial staging and follow-up of invasive or metastatic
Hürthle cell carcinoma.
 As a powerful prognostic tool for identifying which
patients with known distant metastases are at highest
risk for disease-specific mortality.
 As a selection tool to identify those patients unlikely to
respond to additional RAI therapy.
 As a measurement of posttreatment response following
external beam irradiation, surgical resection, emboliza-
tion, or systemic therapy.
As can be seen from the list of indications above, low-risk
patients are very unlikely to require 18FDG-PET scanning as
part of initial staging or follow-up. Additionally, inflamma-
tory lymph nodes, suture granulomas, and increased muscle
activity are common causes of false-positive 18FDG-PET
findings. Therefore, cytologic or histologic confirmation is
required before one can be certain that an 18FDG-positive le-
sion represents metastatic disease.
The sensitivity of 18FDG-PET scanning may be marginally
improved with TSH stimulation (especially in patients with
low Tg values), but the clinical benefit of identifying these
additional small foci is yet to be proven (316).
(d) In addition to its proven role in the localization of
disease in Tg-positive, RAI scan–negative patients,
18FDG-PET scanning may be employed 1) as part of
initial staging in poorly differentiated thyroid cancers
and invasive Hürthle cell carcinomas, especially those
with other evidence of disease on imaging or because
of elevated serum Tg levels, and 2) as a prognostic tool
in patients with metastatic disease to identify those
patients at highest risk for rapid disease progression
and disease-specific mortality, 3) and as an evaluation
of posttreatment response following systemic or local
therapy of metastatic or locally invasive disease. Re-
commendation rating: C
[C10] What is the role of thyroxine TSH suppression
during thyroid hormone therapy in the long-term follow-up of
DTC? A meta-analysis has suggested an association (269)
between thyroid hormone suppression therapy and reduction
of major adverse clinical events. The appropriate degree of
TSH suppression by LT4 is still unknown, especially in high-
risk patients rendered free of disease. One study found that a
constantly suppressed TSH (0.05 mU=L) was associated with
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a longer relapse-free survival than when serum TSH levels
were always 1 mU=L or greater, and that the degree of TSH
suppression was an independent predictor of recurrence in
multivariate analysis (270). Conversely, another large study
found that disease stage, patient age, and 131I therapy inde-
pendently predicted disease progression, but that the degree
of TSH suppression did not (127). A third study showed that
during LT4 therapy the mean Tg levels were significantly
higher when TSH levels were normal than when TSH levels
were suppressed (<0.5 mU=L) but only in patients with local
or distant relapse (317). A fourth study of 2936 patients found
that overall survival improved significantly when the TSH
was suppressed to <0.1 mU=L in patients with NTCTCSG
stage III or IV disease and to 0.1 to about 0.5 range in patients
with NTCTCSG stage II disease; however, there was no in-
cremental benefit from suppressing TSH to undetectable levels
in stage II patients and suppression of TSH was of no benefit in
patients with stage I disease (214). Another recent study found
that a serum TSH threshold of 2 mU=L differentiated best be-
tween patients free of disease and those with relapse or cancer-
related mortality (271). No prospective studies have been
performed examining the risk of recurrence and death from
thyroid cancer associated with varying serum TSH levels,
based on the criteria for the absence of tumor at 6–12 months
postsurgery and RAI ablation outlined above in [C3].
& RECOMMENDATION 49
(a) In patients with persistent disease, the serum TSH
should be maintained below 0.1 mU=L indefinitely
in the absence of specific contraindications. Recom-
mendation rating: B
(b) In patients who are clinically and biochemically free
of disease but who presented with high risk disease,
consideration should be given to maintaining TSH-
suppressive therapy to achieve serum TSH levels of
0.1–0.5 mU=L for 5–10 years. Recommendation rating: C
(c) In patients free of disease, especially those at low risk for
recurrence, the serum TSH may be kept within the low
normal range (0.3–2 mU=L). Recommendation rating: B
(d) In patients who have not undergone remnant ablation
who are clinically free of disease and have undetect-
able suppressed serum Tg and normal neck US, the
serum TSH may be allowed to rise to the low normal
range (0.3–2 mU=L). Recommendation rating: C
[C11] What is the most appropriate management
of DTC patients with metastatic disease?
Metastases discovered during follow-up are likely mani-
festations of persistent disease that has survived initial treat-
ment. Some patients will have a reduction in tumor burden
with additional treatments that may offer a survival or palli-
ative benefit (318–322). The preferred hierarchy of treatment
for metastatic disease (in order) is surgical excision of locor-
egional disease in potentially curable patients, 131I therapy for
RAI-avid disease, external beam radiation, watchful waiting
with patients with stable or slowly progressive asymptomatic
disease, and experimental trials, especially for patients with
significantly progressive macroscopic refractory disease. Ex-
perimental trials may be tried before external beam radiation
in special circumstances, in part because of the morbidity of
external beam radiation and its relative lack of efficacy. A
small fraction of patients may benefit from radiofrequency
ablation (323), ethanol ablation (324), or chemo-embolization
(325). Additionally, surgical therapy in selected incurable
patients is important to prevent complications in targeted
areas, such as the central nervous system (CNS) and central
neck compartment. Conversely, watchful waiting may be
appropriate for selected patients with stable asymptomatic
local metastatic disease, and most patients with stable
asymptomatic non-CNS distant metastatic disease.
[C12] What is the surgical management of locoregional
metastases? Surgery is favored for locoregional (i.e., cervical
lymph nodes and=or soft tissue tumor in the neck) recurrences,
when distant metastases are not present. Approximately one
third to one half of patients may become free of disease in short-
term follow-up (288). It is not clear that treatment of locor-
egional disease is beneficial in the setting of untreatable distant
metastases, except for possible palliation of symptoms or pre-
vention of airway or aerodigestive obstruction. Impalpable
metastatic lymph nodes, visualized on US or other anatomic
imaging modality, that have survived initial 131I therapy
should be considered for resection. Conversely, the benefit to
removing asymptomatic small (<5–8 mm) metastatic lymph
nodes towards improving gross clinical disease recurrences or
disease-specific survival is unproven. When surgery is elected,
most surgeons endorse comprehensive or selective ipsilateral
compartmental dissection of previously unexplored compart-
ments with clinically significant persistent or recurrent disease
(i.e., lymph nodes >0.8 cm in diameter,) while sparing vital
structures (e.g., ipsilateral central neck dissection [level VI],
selective neck dissection levels II–IV, or modified neck dissec-
tion [levels II–V sparing the spinal accessory nerve, the internal
jugular vein, and sternocleidomastoid muscle] (326) as op-
posed to ‘‘berry picking,’’ limited lymph node resection pro-
cedures, or ethanol ablation (324), because microscopic lymph
node metastases are commonly more extensive than would
appear from imaging studies alone (183,327,328). Conversely,
compartmental surgical dissections may not be feasible in the
setting of compartments that have been previously explored
due to extensive scarring, and only a more limited or targeted
lymph node resection may be possible.
& RECOMMENDATION 50
(a) Therapeutic comprehensive compartmental lateral
and=or central neck dissection, sparing uninvolved
vital structures, should be performed for patients with
persistent or recurrent disease confined to the neck.
Recommendation rating: B
(b) Limited compartmental lateral and=or central com-
partmental neck dissection may be a reasonable
alternative to more extensive comprehensive dissec-
tion for patients with recurrent disease within com-
partments having undergone prior comprehensive
dissection and=or external beam radiotherapy. Re-
commendation rating: C
[C13] What is the surgical management of aerodigestive
invasion? For tumors that invade the upper aerodigestive
tract, surgery combined with additional therapy such as 131I
and=or external beam radiation is generally advised (329,330).
Patient outcome is related to complete resection of all gross
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disease with the preservation of function, with techniques
ranging from shaving tumor off the trachea or esophagus for
superficial invasion, to more aggressive techniques when the
trachea is more deeply invaded (e.g., direct intraluminal in-
vasion) including tracheal resection and anastomosis (331–333)
or laryngopharyngoesophagectomy. Patients who are not
curable may undergo less aggressive local treatment in cases of
asphyxia or significant hemoptysis, and as a preliminary step
prior to subsequent radical or palliative treatments (330).
& RECOMMENDATION 51
When technically feasible, surgery for aerodigestive invasive
disease is recommended in combination with RAI and=or
external beam radiotherapy. Recommendation rating: B
[C14] What is the nature of RAI therapy for locoregional or
distant metastatic disease? For regional nodal metastases
discovered on DxWBS, RAI may be employed, although
surgery is typically used in the presence of bulky disease or
disease amenable to surgery found on anatomic imaging such
as US, CT scanning, or MRI. Radioiodine is also used ad-
junctively following surgery for regional nodal disease or
aerodigestive invasion if residual RAI avid disease is present
or suspected.
[C15] Dose and methods of administering 131I for locoregional
or metastatic disease. Despite the apparent effectiveness of
131I therapy in many patients, the optimal therapeutic activity
remains uncertain and controversial (334). There are three
approaches to 131I therapy: empiric fixed amounts, therapy
determined by the upper bound limit of blood and body
dosimetry, and quantitative tumor dosimetry (335). Dosi-
metric methods are often reserved for patients with distant
metastases or unusual situations such as renal insufficiency
(336,337) or when therapy with rhTSH stimulation is deemed
necessary. Comparison of outcome among these methods
from published series is difficult (334). No prospective ran-
domized trial to address the optimal therapeutic approach
has been published. Arguments in favor of higher activities
cite a positive relationship between the total 131I uptake per
tumor mass and outcome (225), while others have not con-
firmed this relationship (338). In the future, the use of 123I or
131I with modern SPECT=CT or 124I PET-based dosimetry may
facilitate whole-body and lesional dosimetry (339,340).
The maximum tolerated radiation absorbed dose (MTRD),
commonly defined as 200 rads (cGy) to the blood, is poten-
tially exceeded in a significant number of patients undergoing
empiric treatment with various amounts of 131I. In one study
(341) 1–22% of patients treated with 131I according to dosim-
etry calculations would have theoretically exceeded the
MTRD had they been empirically treated with 100–300 mCi of
131I. Another study (342) found that an empirically adminis-
tered 131I activity of 200 mCi would exceed the MTRD in
8–15% of patients younger than age 70 and 22–38% of patients
aged 70 years and older. Administering 250 mCi empirically
would have exceeded the MTRD in 22% of patients younger
than 70 and 50% of patients 70 and older.
& RECOMMENDATION 52
(a) In the treatment of locoregional or metastatic disease,
no recommendation can be made about the superiority
of one method of RAI administration over another
(empiric high dose vs. blood and=or body dosimetry
vs. lesional dosimetry.) Recommendation rating: I
(b) Empirically administered amounts of 131I exceeding
200 mCi that often potentially exceed the maximum
tolerable tissue dose should be avoided in patients
over age 70 years. Recommendation rating: A
No randomized trial comparing thyroid hormone with-
drawal therapy to rhTSH-mediated therapy for treatment of
metastatic disease has been reported but there is, despite a
growing body of nonrandomized studies regarding this use
(343–352), one small comparative study that showed the radi-
ation dose to metastatic foci is lower with rhTSH than that
following withdrawal (353). Many of these case reports and
series report disease stabilization or improvement in some
patients following rhTSH-mediated 131I therapy. The use of
rhTSH does not eliminate and may even increase the possibility
of rapid swelling of metastatic lesions (348,354–356).
& RECOMMENDATION 53
There are currently insufficient outcome data to recom-
mend rhTSH-mediated therapy for all patients with meta-
static disease being treated with 131I. Recommendation
rating: D
& RECOMMENDATION 54
Recombinant human TSH–mediated therapy may be in-
dicated in selected patients with underlying comorbidities
making iatrogenic hypothyroidism potentially risky, in
patients with pituitary disease who are unable to raise their
serum TSH, or in patients in whom a delay in therapy
might be deleterious. Such patients should be given the
same or higher activity that would have been given had
they been prepared with hypothyroidism or a dosime-
trically determined activity. Recommendation rating: C
[C16] Use of lithium in 131I therapy. Lithium inhibits io-
dine release from the thyroid without impairing iodine up-
take, thus enhancing 131I retention in normal thyroid and
tumor cells (357). One study (358) found that lithium in-
creased the estimated 131I radiation dose in metastatic tumors
an average of more than twofold, but primarily in those tu-
mors that rapidly cleared iodine. On the other hand, another
more recent study was unable to document any clinical ad-
vantage of lithium therapy on outcome in patients with
metastatic disease, despite an increase in RAI uptake in tumor
deposits (359).
& RECOMMENDATION 55
Since there are no outcome data that demonstrate a better
outcome of patients treated with lithium as an adjunct to
131I therapy, the data are insufficient to recommend lithium
therapy. Recommendation rating: I
[C17] How should distant metastatic disease to various
organs be treated? The overall approach to treatment of
distant metastatic thyroid cancer is based upon the following
observations and oncologic principles:
1. Morbidity and mortality are increased in patients with
distant metastases, but individual prognosis depends
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upon factors including histology of the primary tumor,
distribution and number of sites of metastasis (e.g.,
brain, bone, lung), tumor burden, age at diagnosis
of metastases, and 18FDG and RAI avidity (320,351,
360–366).
2. Improved survival is associated with responsiveness to
surgery and=or RAI (320,351,360–366).
3. In the absence of demonstrated survival benefit, certain
interventions can provide significant palliation or re-
duce morbidity (325,367–369).
4. In the absence of improved survival, palliative benefit,
or reduced potential morbidity, the value of empiric
therapeutic intervention is significantly limited by the
potential for toxicity.
5. Treatment of a specific metastatic area must be con-
sidered in light of the patient’s performance status and
other sites of disease; e.g., 5–20% of patients with dis-
tant metastases die from progressive cervical disease
(366,370).
6. Longitudinal re-evaluation of patient status and con-
tinuing re-assessment of potential benefit and risk of
intervention is required.
7. The overall poor outcome of patients with radio-
graphically evident or symptomatic metastases that do
not respond to RAI, the complexity of multidisciplinary
treatment considerations and the availability of pro-
spective clinical trials should encourage the clinician to
refer such patients to tertiary centers with particular
expertise.
[C18] Treatment of pulmonary metastases. In the manage-
ment of the patient with pulmonary metastases, key criteria
for therapeutic decisions include 1) size of metastatic lesions
(macronodular typically detected by chest radiography; mi-
cronodular typically detected by CT; lesions beneath the res-
olution of CT); 2) avidity for RAI and, if applicable, response
to prior RAI therapy; and 3) stability (or lack thereof ) of
metastatic lesions. Pulmonary pneumonitis and fibrosis are
rare complications of high-dose radioactive iodine treatment.
Dosimetry studies with a limit of 80 mCi whole-body reten-
tion at 48 hours and 200 cGy to the red bone marrow should
be considered in patients with diffuse 131I pulmonary uptake
(371). If pulmonary fibrosis is suspected, then appropriate
periodic pulmonary function testing and consultation should
be obtained. The presence of pulmonary fibrosis may limit the
ability to further treat metastatic disease with RAI.
& RECOMMENDATION 56
Pulmonary micrometastases should be treated with RAI
therapy, and repeated every 6–12 months as long as disease
continues to concentrate RAI and respond clinically, be-
cause the highest rates of complete remission are reported
in these subgroups (360,365,372,373). Recommendation
rating: A
& RECOMMENDATION 57
The selection of RAI activity to administer for pulmonary
micrometastases can be empiric (100–200 mCi) or estimated
by dosimetry to limit whole-body retention to 80 mCi at
48 hours and 200 cGy to the red bone marrow. Recom-
mendation rating: B
Macronodular pulmonary metastases may also be treated
with RAI if demonstrated to be iodine avid. How many doses
of RAI to give and how often to give it is a decision that must
be individualized based on the disease response to treatment,
the rate of disease progression in between treatments, age of
the patient, the presence or absence of other metastatic lesions,
and the availability of other treatment options including
clinical trials (360,365).
& RECOMMENDATION 58
Radioiodine-avid macronodular metastases should be trea-
ted with RAI and treatment should be repeated when ob-
jective benefit is demonstrated (decrease in the size of the
lesions, decreasing Tg), but complete remission is not com-
mon and survival remains poor. The selection of RAI activity
to administer can be made empirically (100–200 mCi) or
estimated by lesional dosimetry or dosimetry to limit whole-
body retention to 80 mCi at 48 hours and 200 cGy to the red
bone marrow. Recommendation rating: B
[C19] Non–RAI-avid pulmonary disease. Radioiodine is of
no benefit in patients with non–RAI-avid disease. In the
setting of a negative diagnostic RAI scan, micronodular
pulmonary metastases may demonstrate a positive post-
treatment scan and measurable benefit to RAI therapy,
whereas this is unlikely in the setting of macronodular me-
tastases. In one study, administration of 200–300 mCi of RAI
to 10 patients with pulmonary macrometastases who had
negative 3 mCi diagnostic scans was associated with a five-
fold increase in the median TSH-suppressed Tg, and death
was reported in several patients within 4 years of treatment
(374). Although not specifically limited to pulmonary lesions,
patients with increasing volumes of 18FDG-avid disease seen
on PET scans were less likely to respond to RAI and more
likely to die during a 3-year follow-up compared with 18FDG-
negative patients (375). Another study found that RAI ther-
apy of metastatic lesions that were positive on 18FDG-PET
scanning was of no benefit (376). In other studies of 18FDG-
PET imaging, however, insufficient details exist in patients
known to have pulmonary metastases to assess the utility of
this modality to predict treatment response or prognosis
(377). A study (378) that retrospectively examined the clinical
course of 400 thyroid cancer patients with distant metastases
who had undergone 18FDG-PET scanning found that al-
though age, initial tumor stage, histology, Tg level, RAI up-
take, and PET outcomes all correlated with survival by
univariate analysis, only age and PET results were strong
predictors of survival. There were significant inverse rela-
tionships between survival and both the glycolytic rate of the
most active lesion and the number of 18FDG-avid lesions. The
study found tumors that did not concentrate 18FDG had a
significantly better prognosis after a median follow-up of
about 8 years than did tumors that avidly concentrated
18FDG.
Most studies evaluating systemic therapy for metastatic
disease have focused on patients with pulmonary metastases.
Traditional cytotoxic chemotherapeutic agents, such as
doxorubicin and cisplatin, are generally associated with no
more than 25% partial response rates, complete remission has
been rare, and toxicities from these treatments are consider-
able (379). Doxorubicin monotherapy, which remains the only
treatment for metastatic thyroid carcinoma approved by the
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U.S. Food and Drug Administration, is occasionally effective
when dosed appropriately (60–75 mg=m2 every 3 weeks)
(380–383), but durable responses are uncommon. Most stud-
ies of combination chemotherapy show no increased response
over single agent doxorubicin and increased toxicity (384).
Some specialists recommend consideration of single agent
doxorubicin or paclitaxel, or a combination of these agents,
based on limited data in anaplastic thyroid carcinoma (385).
One recent study evaluated the effect of combination che-
motherapy (carboplatinum and epirubicin) under TSH stim-
ulation (endogenous or rhTSH) (386), demonstrating an
overall rate of complete and partial response of 37%. These
data need to be confirmed prior to consideration for general
use. Recently published phase II trials suggest that anti-
angiogenic therapies may produce partial response rates of
up to 31% and stabilize another 40–50% of patients with
progressive metastatic disease (387–391). Clinical benefit
lasting at least 24 weeks was observed in about half of
patients. The orally available anti-angiogenic tyrosine kinase
inhibitors (axitinib, motesanib, and sorafenib) have numerous
common side effects, including hypertension, diarrhea,
fatigue, skin rashes and erythema, and weight loss, and var-
ious drug-specific toxicities have been reported as well. These
side effects, although often mild and responsive to supportive
care measures, justify suggesting that treatment with these
agents should be limited to specialists experienced in their
use. Similar results are also being reported with use of suni-
tinib, but phase II studies are still ongoing. Serum TSH levels
may increase with the use of these agents. Serum TSH should
be monitored, and the thyroxine dose increased as needed.
Multiple other agents are in clinical trials, targeting pathways
involved in angiogenesis, cell cycle regulation, and tumor
differentiation.
If the patient qualifies for a clinical trial, they should con-
sider bypassing traditional chemotherapy and moving di-
rectly to clinical trials. However, often patients cannot
participate in clinical trials because of the time and expense
required, or failure to meet strict eligibility criteria. Most
available trials can be found listed at www.clinicaltrials.
gov, www.nci.nih.gov, www.centerwatch.com, or www.
thyroid.org.
& RECOMMENDATION 59
(a) Evidence of benefit of routine treatment of non–RAI-
avid pulmonary metastases is insufficient to recom-
mend any specific systemic therapy. For many
patients, metastatic disease is slowly progressive and
patients can often be followed conservatively on TSH-
suppressive therapy with minimal evidence of radio-
graphic or symptomatic progression. For selected
patients, however, other treatment options need to be
considered, such as metastasectomy, endobronchial
laser ablation, or external beam radiation for palliation
of symptomatic intrathoracic lesions (e.g., obstructing
or bleeding endobronchial masses), and pleural or
pericardial drainage for symptomatic effusions. Re-
ferral for participation in clinical trials should be con-
sidered. Recommendation rating: C
(b) Referral for participation in clinical trials should be
considered for patients with progressive or symp-
tomatic metastatic disease. For those patients who do
not participate in clinical trials, treatment with tyrosine
kinase inhibitors should be considered. Recommenda-
tion rating: B
[C20] Treatment of bone metastases. In the management of
the patient with bone metastases, key criteria for therapeutic
decisions include 1) the presence of or the risk for pathologic
fracture, particularly in a weight-bearing structure; 2) risk for
neurologic compromise from vertebral lesions; 3) presence of
pain; 4) avidity of RAI uptake; and 5) potential significant
marrow exposure from radiation arising from RAI-avid pelvic
metastases.
& RECOMMENDATION 60
Complete surgical resection of isolated symptomatic me-
tastases has been associated with improved survival and
should be considered, especially in patients <45 years old
with slowly progressive disease (320,363). Recommenda-
tion rating: B
& RECOMMENDATION 61
RAI therapy of iodine-avid bone metastases has been as-
sociated with improved survival and should be employed
(320,365), although RAI is rarely curative. The RAI activity
administered can be given empirically (100–200 mCi) or
determined by dosimetry (225). Recommendation rating: B
& RECOMMENDATION 62
When skeletal metastatic lesions arise in locations where
acute swelling may produce severe pain, fracture, or neu-
rologic complications, external radiation and the concom-
itant use of glucocorticoids to minimize potential TSH-
induced and=or radiation-related tumor expansion should
be strongly considered (392). Recommendation rating: C
& RECOMMENDATION 63
Painful lesions that cannot be resected can also be treated
by several options individually or in combination, includ-
ing RAI, external beam radiotherapy, intra-arterial embo-
lization (325,393), radiofrequency ablation (394), periodic
pamidronate or zoledronate infusions (with monitoring for
development of possible mandibular osteonecrosis) (369),
or verteboplasty or kyphoplasty (395). While many of these
modalities have been shown to relieve bone pain in cancer,
they have not necessarily been reported to have been used
in thyroid cancer patients. Recommendation rating: C
& RECOMMENDATION 64
Evidence is insufficient to recommend treatment of
asymptomatic, non–RAI-responsive, stable lesions that do
not threaten nearby critical structures. Recommendation
rating: I
[C21] Treatment of brain metastases. Brain metastases typ-
ically occur in older patients with more advanced disease and
are associated with a poor prognosis (351). Surgical resection
and external beam radiotherapy traditionally have been the
mainstays of therapy (351,396). There are few data showing
efficacy of RAI.
& RECOMMENDATION 65
Complete surgical resection of CNS metastases should
be considered regardless of RAI avidity, because it is
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associated with significantly longer survival. Recommen-
dation rating: B
& RECOMMENDATION 66
CNS lesions that are not amenable to surgery should be
considered for external beam irradiation. Optimally, very
targeted approaches (such as radiosurgery) are employed
to limit the radiation exposure of the surrounding brain
tissue. Whole brain and spine irradiation could be consid-
ered if multiple metastases are present. Recommendation
rating: C
& RECOMMENDATION 67
If CNS metastases do concentrate RAI, then RAI could be
considered. If RAI is being considered, prior external beam
radiotherapy and concomitant glucocorticoid therapy are
strongly recommended to minimize the effects of a poten-
tial TSH-induced increase in tumor size and the subsequent
inflammatory effects of the RAI (392). Recommendation
rating: C
[C22] What is the management of complications
of RAI therapy?
While RAI appears to be a reasonably safe therapy, it is
associated with a cumulative dose-related low risk of early-
and late-onset complications such as salivary gland damage,
dental caries (397), nasolacrimal duct obstruction (398), and
secondary malignancies (157,281,399,400). Therefore, it is
important to ensure that the benefits of RAI therapy, espe-
cially repeated courses, outweigh the potential risks. There is
probably no dose of RAI that is completely safe nor is there
any maximum cumulative dose that could not be used in
selected situations. However, with higher individual and
cumulative doses there are increased risks of side effects as
discussed previously.
For acute transient loss of taste or change in taste and sia-
ladentitis, recommended measures to prevent damage to the
salivary glands have included amifostine, hydration, sour
candies, and cholinergic agents (401), but evidence is insuffi-
cient to recommend for or against these modalities. One re-
cent study suggested sour candy may actually increase
salivary gland damage when given within 1 hour of RAI
therapy, as compared to its use until 24 hours posttherapy
(402). For chronic salivary gland complications, such as dry
mouth and dental caries, cholinergic agents may increase
salivary flow (401).
& RECOMMENDATION 68
The evidence is insufficient to recommend for or against
the routine use of preventive measures to prevent salivary
gland damage after RAI therapy. Recommendation rating: I
& RECOMMENDATION 69
Patients with xerostomia are at increased risk of dental
caries and should discuss preventive strategies with their
dentists. Recommendation rating: C
& RECOMMENDATION 70
Surgical correction should be considered for nasolacrimal
outflow obstruction, which often presents as excessive
tearing (epiphora) but also predisposes to infection. Re-
commendation rating: B
[C23] What is the risk of second malignancies and leu-
kemia from RAI therapy? Most long-term follow-up studies
variably report a very low risk of secondary malignancies
(bone and soft tissue malignancies, including breast, colo-
rectal, kidney, and salivary cancers, and myeloma and leu-
kemia) in long-term survivors (157,281). A meta-analysis of
two large multicenter studies showed that the risk of second
malignancies was significantly increased at 1.19 (95% CI:
1.04–1.36; p< 0.010), relative to thyroid cancer survivors not
treated with RAI (403). The risk of leukemia was also signif-
icantly increased in thyroid cancer survivors treated with
RAI, with a relative risk of 2.5 (95% CI: 1.13–5.53; p< 0.024)
(403). The risk of secondary malignancies is dose related (157),
with an excess absolute risk of 14.4 solid cancers and of 0.8
leukemias per gigabecquerel of 131I at 10,000 person-years of
follow-up. Cumulative 131I activities above 500–600 mCi are
associated with a significant increase in risk. There appears to
be an increased risk of breast cancer in women with thyroid
cancer (281,399,404). It is unclear whether this is due to
screening bias, RAI therapy, or other factors. An elevated risk
of breast cancer with 131I was not observed in another study
(282). The use of laxatives may decrease radiation exposure of
the bowel, and vigorous oral hydration will reduce exposure
of the bladder and gonads (15).
& RECOMMENDATION 71
Because there is no evidence demonstrating a benefit of
more intensive screening, all thyroid cancer patients should
be encouraged to seek age-appropriate screenings for
cancer according to routine health maintenance recom-
mendations. Patients who receive a cumulative 131I activity
in excess of 500–600 mCi should be advised that they may
have a small excess risk of developing leukemia and solid
tumors in the future. Recommendation rating: C
[C24] What are other risks to the bone marrow from RAI
therapy? Published data indicate that when administered
activities are selected to remain below 200 cGy to the bone
marrow, minimal transient effects are noted in white blood
cell and platelet counts (371). However, persistent mild dec-
rements in white blood cell count and=or platelets are not
uncommon in patients who have received multiple RAI
therapies. Further, radiation to the bone marrow is impacted
by several factors, including renal function.
& RECOMMENDATION 72
Patients receiving therapeutic doses of RAI should have
baseline CBC and assessment of renal function. Recom-
mendation rating: C
[C25] What are the effects of RAI on gonadal function and
in nursing women? Women about to receive radioactive
iodine therapy should first undergo pregnancy testing. Go-
nadal tissue is exposed to radiation from RAI in the blood,
urine, and feces. Temporary amenorrhea=oligomenorrhea
lasting 4–10 months occurs in 20–27% of menstruating
women after 131I therapy for thyroid cancer. Although the
numbers of patients studied are small, long-term rates of in-
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fertility, miscarriage, and fetal malformation do not appear to
be elevated in women after RAI therapy (405–407). One large
retrospective study suggested that pregnancy should be
postponed for 1 year after therapy because of an increase in
miscarriage rate (408), although this was not confirmed in
another similarly designed study (409). Ovarian damage from
RAI therapy may result in menopause occurring approxi-
mately 1 year earlier than the general population, but this
result was not associated with cumulative dose administered
or the age at which the therapy was given (410). In men, RAI
therapy may be associated with a temporary reduction in
sperm counts and elevated serum follicle-stimulating hor-
mone (FSH) levels (411,412). Higher cumulative activities
(500–800 mCi) in men are associated with an increased risk of
persistent elevation of serum FSH levels, but fertility and risks
of miscarriage or congenital abnormalities in subsequent
pregnancies are not changed with moderate RAI activities
(*200 mCi) (413,414). Permanent male infertility is unlikely
with a single ablative activity of RAI, but theoretically there
could be cumulative damage with multiple treatments. It has
been suggested that sperm banking be considered in men who
may receive cumulative RAI activities 400 mCi (412). Go-
nadal radiation exposure is reduced with good hydration,
frequent micturition to empty the bladder, and avoidance of
constipation (415).
& RECOMMENDATION 73
Women receiving RAI therapy should avoid pregnancy for
6–12 months. Recommendation rating: C
& RECOMMENDATION 74
(a) Radioactive iodine should not be given to nursing
women. Depending on the clinical situation, RAI
therapy could be deferred until a time when lactating
women have stopped breast-feeding for at least 6–8
weeks. Recommendation rating: B
(b) Dopaminergic agents might be useful in decreasing
breast exposure in recently lactating women, although
caution should be exercised given the risk of serious
side effects associated with their routine use to sup-
press postpartum lactation. Recommendation rating: C
[C26] What is the management of Tg-positive,
RAI scan–negative patients?
If the unstimulated Tg is or becomes detectable, or in-
creases over time, or if stimulated Tg levels rise to greater
than 2 ng=mL, imaging of the neck and chest should be
performed to search for metastatic disease, typically with
neck US and with thin cut (5–7 mm) helical chest CT. Iodi-
nated contrast should be avoided if RAI therapy is planned
within the subsequent few months, although intravenous
contrast may aid in identification of cervical and mediastinal
disease. In addition, for patients with a prior history of
metastatic cervical lymph nodes in the anterior compart-
ments, cross-sectional imaging with either neck CT or MRI
should be considered to evaluate the retropharyngeal lymph
nodes that cannot be imaged by sonography. If imaging is
negative for disease that is potentially curable by surgery, or
the serum Tg appears out of proportion to the identified
surgically resectable disease, then whole-body 18FDG-PET
imaging may be obtained if the stimulated serum Tg is
>10 ng=mL. If the 18FDG PET scan is negative, then empiric
therapy with RAI (100–200 mCi) should be considered to aid
localization or for therapy of surgically incurable disease
(Fig. 5). This approach may identify the location of persistent
disease in approximately 50% of patients (307,416) with a
wide range of reported success. Some investigators have
reported a fall in serum Tg after empiric RAI therapy in
patients with negative DxWBS (417,418), but there is no ev-
idence for improved survival with empiric therapy in this
setting (374,418). On the other hand, Tg levels may decline
without specific therapy during the first years of follow-up
(418).
When the RxWBS after empiric 131I therapy is negative,
18FDG-PET scanning is indicated if not already obtained. In-
tegrated 18FDG-PET=CT is able to improve diagnostic accu-
racy of 18FDG-PET in patients with iodine-negative tumors. In
a study of 40 such patients, in whom PET and CT images were
scored blindly, the diagnostic accuracy was 93% for inte-
grated 18FDG-PET=CT and 78% for PET alone ( p< 0.5) (419).
In 74% of the patients with suspicious 18FDG foci, integrated
18FDG-PET=CT added relevant information to the side-by-
side interpretation of PET and CT images by precisely local-
izing the lesions. 18FDG-PET=CT fusion studies led to a
change of therapy in 48% of the patients. In another study,
18FDG-PET=CT changed the clinical management of 44% of 61
patients, including surgery, radiation therapy, or chemo-
therapy (420). The rate of PET scan positivity is low (11–13%)
in patients with stimulated Tg levels <10 ng=mL (421,422).
Some have argued that 18FDG-PET scanning should be per-
formed prior to empiric RAI therapy (423), since tumors that
are 18FDG-PET positive do not generally concentrate RAI
(376), and RAI therapy is unlikely to alter the poorer outcome
in such patients (378).
A cutoff value of Tg above which a patient should be
treated with an empiric dose of RAI is difficult to determine,
due in part to the wide variation in available Tg assays (in-
cluding those used in reports suggesting benefit of such
therapy) and the differences in Tg levels based on method and
degree of TSH stimulation or suppression. Recent studies
have reported primarily on patients with Tg levels after T4
withdrawal of 10 ng=mL or higher, and it has been suggested
that a corresponding level after rhTSH stimulation would be
5 ng=mL (308,374,416,418,424). A Tg level that is rising may
warrant greater concern for the need for empiric therapy, al-
though data regarding the appropriate rate of change are
minimal (301). However a detectable but low Tg level at 9–12
months following remnant ablation may not warrant further
therapy.
& RECOMMENDATION 75
Empiric radioactive iodine therapy (100–200 mCi) might be
considered in patients with elevated (Tg levels after T4
withdrawal of 10 ng=mL or higher, or a level of 5 ng=mL or
higher after rhTSH stimulation) or rising serum Tg levels in
whom imaging has failed to reveal a potential tumor source.
If the posttherapy scan is negative, no further RAI therapy
should be administered. Recommendation rating: C
& RECOMMENDATION 76
If persistent nonresectable disease is localized after an
empiric dose of RAI, and there is objective evidence of
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ALGORITHM for MANAGEMENT of DTC
TWELVE or more MONTHS after REMNANT ABLATION 
Declining Serum Tg or 
Tg <1 with Declining 
TgAb Present 
History of Poor 
Response to RAI 
Therapy  
Bulky Tumor Present 
Grade 3 Blood/Bone 
Marrow Compromisec
Present 
Do Not Treat with
131-Iodine
Consider Surgery/EBRT/Clinical Trials
Patient Unable to Raise 
TSH or Tolerate THW 
History of CT Contrast in Past 3–4 Months or of 





Consider 131I Therapy 
with 100 to 150 mCi  
1–2 Week Low-  
Iodine Diet  
Low 
High 
5–8 Day Post Rx WBS Result Negative 
Positive 
Continue 131I if Beneficiald
False Elevation in Serum 
Tg or Evidence of 
Heterophile Antibody 
Interference Present b
Empiric 131I Therapy Under Consideration:  Evaluate History of Prior Therapy, 
Response to Therapy, Confounding Factors, and Current Staging of Patient as 
Assessed by Physical Examination, Laboratory Tests, and Imaging Studiesa 
131I Therapy with 100 to 150 mCi 
when TSH >30 or after rhTSH e
18FDG-PET/CT if Not Done 
FIG. 5. Considerations for empiric treatment with radioiodine.
aEmpiric 131I therapy should be done with meticulous patient preparation, including low-iodine diet and, if iodine con-
tamination is a possibility, urinary iodine measurements. If the RxWBS is negative or subsequent follow-up studies show no
therapeutic benefit, further empiric 131I should not be administered.
bTg that rises with TSH stimulation and falls with TSH suppression is unlikely to result from heterophile antibodies.
cNational Cancer Institute Common Terminology Criteria for Adverse Events, Version 3.0, (http:==ctep.cancer.gov).
dDosimetry could be considered to allow administration of maximum radioiodine activity if the tumor is life-threatening.
eA dose of 200 mCi could exceed the maximum tolerable dose in older individuals (see Recommendation 52b).
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significant tumor reduction, then RAI therapy should be
repeated until the tumor has been eradicated or the tumor
no longer responds to treatment. The risk of repeated
therapeutic doses of RAI must be balanced against uncer-
tain long-term benefits. Recommendation rating: C
& RECOMMENDATION 77
In the absence of structurally evident disease, stimulated
serum Tg<10 ng=mL with thyroid hormone withdrawal or
<5 ng=mL with rhTSH can be followed with continued LT4
therapy alone, reserving additional therapies for those
patients with rising serum Tg levels over time or other
evidence of structural disease progression. Recommenda-
tion rating: C
[C27] What is the management of patients with a negative
RxWBS?
& RECOMMENDATION 78
(a) If an empiric dose (100–200 mCi) of RAI fails to localize
the persistent disease, 18FDG-PET=CT scanning should
be considered, especially in patients with unstimulated
serum Tg levels >10–20 ng=mL or in those with ag-
gressive histologies, in order to localize metastatic le-
sions that may require treatment or continued close
observation (425,426). Recommendation rating: B
Stimulation with endogenous TSH following thyroxine
withdrawal or rhTSH (316) and CT fusion (427) may mini-
mally enhance the sensitivity and specificity of 18FDG-PET
scanning.
(b) Tg-positive, RxWBS-negative patients with disease
that is incurable with surgery and is structurally evi-
dent or visualized on 18FDG-PET=CT scan can be
managed with thyroid hormone suppression therapy,
external beam radiotherapy, chemotherapy, radio-
frequency ablation, chemo-embolization, or monitor-
ing without additional therapy if stable. Clinical trials
should also be considered. Recommendation rating: C
& RECOMMENDATION 79
Tg-positive, RxWBS-negative patients with no structural
evidence of disease can be followed with serial structural
imaging studies and serial Tg measurements, with both
performed more frequently if the Tg level is rising. When
and how often to repeat 18FDG-PET=CT imaging in this
setting is less certain. Recommendation rating: C
[C28] What is the role of external beam radiotherapy
in treatment of metastatic disease?
& RECOMMENDATION 80
External beam radiation should be used in the management
of unresectable gross residual or recurrent cervical disease,
painful bone metastases, or metastatic lesions in critical
locations likely to result in fracture, neurological, or com-
pressive symptoms that are not amenable to surgery (e.g.,
vertebral metastases, CNS metastases, selected mediastinal
or subcarinal lymph nodes, pelvic metastases) (277). Re-
commendation rating: B
[D1] WHAT ARE DIRECTIONS FOR FUTURE RESEARCH?
[D2] Novel therapies and clinical trials
While surgery and the judicious use of RAI, as described in
these guidelines, is sufficient treatment for the majority of
patients with DTC, a minority of these patients experience
progressive, life-threatening growth and metastatic spread of
the disease. The recent explosion of knowledge regarding the
molecular and cellular pathogenesis of cancer has led to the
development of a range of targeted therapies, now undergoing
clinical evaluation. Efficacy has already been demonstrated for
several agents in phase II studies, including axitinib, motesanib,
sorafenib, pazopanib, and thalidomide, whereas many others
are in ongoing trials. Randomized phase III trials to demon-
strate improved survival, improved progression free survival,
or superiority of one therapy over another have not been per-
formed, however, and none of these drugs have been specifi-
cally approved for treatment of metastatic thyroid carcinoma.
These therapies can be grouped into a number of categories.
[D3] Inhibitors of oncogenic signaling pathways. Tyrosine
kinase inhibitors of interest in thyroid carcinoma usually target
transmembrane tyrosine kinase receptors that initiate signal-
ing through the MAP kinase pathway. This signaling pathway
is activated in the majority of PTCs. Inhibitors of RET, RAS,
RAF, and MEK kinases target various members of the same
signaling pathway. Several of these agents are in development
with several clinical trials completed or underway. Specific
oncogene targeting for follicular thyroid cancer and Hürthle cell
cancer awaits better understanding of the pathways involved
in initiation of these tumor types, although responses in pa-
tients with these subtypes have been reported in clinical trials.
[D4] Modulators of growth or apoptosis. Key components
of growth and apoptotic pathways are targeted by PPARg
activators, including COX2 inhibitors; rexinoids, which acti-
vate RXR; bortezomib, which inactivates the cancer pro-
teasome; and derivatives of geldanomycin, which target the
hsp-90 protein. Clinical trials in thyroid cancer of each of these
agents are available.
[D5] Angiogenesis inhibitors. Targeting of vascular en-
dothelial growth factor (VEGF) receptors and other members
of the signaling cascades responsible for neoangiogenesis may
limit the growth of cancers by restricting their blood supply.
Many of the kinase inhibitors that have been studied to date
are very potent inhibitors of the tyrosine kinase of the VEGF
receptors. Trials of several of these agents are currently un-
derway in all subtypes of thyroid cancer.
[D6] Immunomodulators. Stimulation of the immune re-
sponse to cancer may be achieved by augmenting the activity
of antigen-presenting dendritic cells. This approach has
shown possible benefits in phase I clinical trials, but has not
yet been studied in thyroid cancer. The apparent immuno-
genicity of thyroid cells makes this an attractive approach for
future clinical trials.
[D7] Gene therapy. Preclinical studies have demon-
strated some efficacy in thyroid cancer cell lines. Approaches
include introducing toxic genes under the control of thyroid-
specific promoters, or restoration of the p53 tumor suppressor
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gene in anaplastic thyroid cancer cell lines. Problems with
gene delivery limit the clinical utility of these approaches,
which have not yet reached clinical trials in thyroid cancer.
Each of these targeted approaches holds promise for our
future ability to treat patients with life-threatening disease
unresponsive to traditional therapy. In the meantime, for
appropriate patients, entry into one of the available clinical
trials may be an attractive option.
[D8] Better understanding of the long-term risks of RAI
With the more widespread use of RAI in the management
of thyroid cancer, and the normal life expectancy of most
patients with the disease, it is imperative that we have a better
understanding of the long-term risks associated with its use.
Research that focuses on how to minimize the impact of RAI
on the salivary glands in order to prevent sialadenitis and
xerostomia would provide a significant benefit to patients. A
better understanding of the long-term effects of RAI on re-
productive issues in men and women is also an important
topic. Finally, while the risk of second malignancies appears
small following the usual activities of RAI used for remnant
ablation, we need better understanding of the long-term risks
for salivary gland tumors, bladder tumors, and colon cancers
when repeated doses of RAI are needed in young patients
who are potentially long-term survivors of thyroid cancer.
[D9] Clinical significance of persistent low
levels of serum Tg
After initial surgery and RAI therapy some patients will
have persistently detectable stimulated serum Tg when eval-
uated 9–12 months later. Most of these patients have stimu-
lated Tg levels in the range of 1–10 ng=mL, levels typically
associated with a small volume of tissue. Some of these patients
demonstrate a subsequent spontaneous fall in Tg over time,
others remain stable, while still others demonstrate rising Tg
levels. The optimal management of these patients is unknown.
How often should they undergo neck US or stimulated serum
Tg testing? Will sensitive Tg assays combined with neck US
replace stimulation testing? Which (if any) of these patients
should undergo chest CT, PET, or empiric RAI therapy? Can
we improve our abilities to predict and monitor which patients
are likely to be harmed by their disease as opposed to those
who will live unaffected by theirs? Does metastatic disease in
small local lymph nodes have the potential to metastasize to
distant sites during observation while on TSH suppression
therapy? The current impetus to test and treat all of these pa-
tients is based on the argument that early diagnosis may lead to
early treatment of residual disease when treatment is more
likely to be effective, as opposed to less effective treatment
when the tumor is more bulky, more extensive, or has spread to
inoperable locations. However, there is no current proof that
aggressive treatment of minimal residual disease improves
patient outcome. This is brought into focus by the fact that only
about 5% of all PTC patients die of their disease, yet 15–20% of
low-risk PTC patients are likely to have persistent disease
based on persistent measurable Tg with stimulation testing.
[D10] The problem of Tg antibodies
Anti-Tg antibodies are a common clinical problem in
patients with DTC (305). The presence of these antibodies
usually interferes with serum Tg measurement and recovery
assays do not appear to accurately predict this interference
(305,428). Decreasing antibody levels are correlated with
‘‘disease-free’’ status while increasing levels suggest persistent
disease (306,429). However, there are clear exceptions to this
‘‘rule.’’ These patients are therefore a challenge to manage or
study because one often can not be certain of their disease
status. This problem limits definitive investigation which, in
turn, hampers development of evidence-based guidelines
such as these to assist clinicians. Measurement of Tg mRNA in
the blood may be a sensitive marker for persistent thyroid
cells even in the presence of anti-Tg antibodies (430–432), but
RNA extraction is not well standardized and some studies
question the specificity of this marker (433,434). Future
studies optimizing the measurement of Tg mRNA and per-
haps other thyroid-related substances in blood from DTC
patients with anti-Tg antibodies are needed to better monitor
this challenging subgroup of DTC patients. This goal would
also be enhanced by development of Tg assays that have
limited interference by anti-Tg antibodies and by methods to
clear anti-Tg antibodies prior to Tg measurement.
[D11] Small cervical lymph node metastases
The rates of cervical lymph node metastases generally range
from about 20% to 50% in most large series of DTC, with higher
rates in children or when micrometastases are considered. The
location and number of lymph node metastases is often diffi-
cult to identify before, during, or after surgery, especially mi-
crometastases. Although postoperative 131I given to ablate the
thyroid remnant undoubtedly destroys some micrometastases,
the most common site of recurrence is in cervical lymph nodes,
which comprise the majority of all recurrences. Future research
must consider the dilemma of minimizing iatrogenic patient
harm versus preventing cancer morbidity and (perhaps) mor-
tality. Perhaps techniques will be developed to safely remove
or destroy small cervical nodal metastases, which in some cases
would otherwise progress to overt, clinically significant me-
tastases. Conversely, the clinical significance of very small
(<0.5 cm) nodal metastases needs to be clarified by long-term
follow-up studies. Development of a cost-effective method to
determine which metastases can be safely followed without
intervention would be of great benefit.
[D12] Improved risk stratification
Current risk stratification schemes rely almost exclusively
on clinical, pathological, and radiological data obtained dur-
ing the initial evaluation and therapy of the patient. However,
none of the commonly used risk stratification schemes ade-
quately incorporate the prognostic implications of the very
detailed pathological descriptions that are provided (e.g.,
various histological subtypes of thyroid cancer, frequent mi-
toses, areas of tumor necrosis, minor degrees of extrathyroidal
extension, or capsular invasion) or the molecular character-
istics of the primary tumor. Furthermore, current staging
systems are static representations of the patient at the time of
presentation and are not easily modifiable over time as new
data become available during follow-up. Therefore, a risk
stratification system that incorporates all the important in-
formation available at presentation and also evolves over time
as new data become available would be useful in providing
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ongoing risk assessments that would optimize management
throughout the life of the patient.
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